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Hearing is one of our most important senses. It is a prerequisite in the development of 
speech in a child. Hearing and speech are intertwined and define us as social animals. 
It is the medium through which we interact with our environment and the people 
around us and without it, communication would come to a near standstill. With 
this in mind, to suddenly lose your hearing is a dramatic event. Future plans and 
aspirations must be redefined and a path must be found towards acceptance of the 
change in communication. Add to this the nearly always present tinnitus and vestibular 
symptoms and sudden deafness becomes a real problem. This is the background 
against which many patients come to an ENT specialist asking for help. It is a sobering 
thought that so far, treatment results for sudden deafness have been disappointing. 
Especially in the context of the modern world, where there are supposed to be cures 
for almost every illness. The idiopathic character of sudden hearing loss provides 
little to guide aetiology or treatment. Since De Kleyn suggested a vascular incident 
as being a cause of sudden hearing loss in 1 944, theories have abounded 1 • After 
more than sixty years of research the three main theories regarding the aetiology of 
idiopathic sudden sensorineural hearing loss (ISSHL) are viral infections of the inner 
ear 2• 2• 3, disturbances in the microcirculation 4 and cochlear membrane ruptures5, or 
a combination thereof. Treatment modalities mirror these uncertainties. Many drugs 
have been tried, including vasodilators, plasma expanders, intravenous contrast agents, 
carbogen inhalation, corticosteroids, or all of them at once as 'shotgun therapy' 6, some 
with more success than others, but none with fully satisfactory results. 
Elucidation of the aetiology might be possible if diagnostic samples could be taken 
from the inner ear. However, this would almost certainly lead to irreversible damage to 
the inner ear and permanent hearing loss for the patient. The natural history ofiSSHL 
shows some spontaneous hearing recovery in 45-65% of patients, although few recover 
completely 2• This makes diagnostic sampling ethically unfeasible. A second problem 
is that the low incidence ofiSSHL impedes large clinical studies which eventually can 
lead us to optimal treatment results. 
This thesis builds upon the results described in the thesis by R.J. Stokroos, entitled 
Idiopathic Sudden Sensorineural Hearing Loss ( 1997) 7• In this thesis a literature 
survey of etiology and therapy of ISSHL provides the basis for the theory that a 
subclinical viral labyrinthitis plays an important part in the pathophysiology ofiSSHL. 
Two animal models are presented in which the emphasis lies on a Herpes simplex virus 
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type 1 (HSV-1) labyrinthitis. In one study the histopathological effects are compared 
to the histopathological findings in ISSHL, in the other study the efficacy of acidovir 
and prednisone are evaluated as a treatment in HSV-1 labyrinthitis. A Gadolinium 
enhanced MRI can be used to identify a (sub)dinical labyrinthitis, but only in the 
very first phase of the labyrinthitis. In the last chapter, a prospective, randomized, 
double-blind placebo-controlled clinical study is presented where 44 patients with 
ISSHL receive prednisone with double-blind acidovir or placebo. No beneficial 
effect of aciclovir as adjuvant to prednisone on hearing recovery could be proven. 
The thesis still left a number of questions unanswered. Was the theory wrong or were 
there methodological shortcomings? Are there more ways to treat this hypothesized 
(sub)clinical labyrinthitis? We have tried to address some of these remaining issues. 
OUTLINE OF THE THESIS 
The aim of this thesis is to systematically evaluate two therapies for ISSHL. Our 
hypothesis is that an immune reaction, probably virally induced, in the inner ear 
is responsible for the sudden hearing loss. Based on the knowledge that steroids 
exert a small but clinically relevant effect on hearing recovery, we feel it is unethical 
to withhold this treatment from patients. In our studies we compared the trial 
medication with a tapered course of prednisone of 7 days. All patients with sudden 
hearing loss underwent a diagnostic protocol which included a complete history and 
physical examination, audiological and vestibular tests, magnetic resonance imaging 
of the temporal bone and cerebellopontine angle, and laboratory workup. 
Laboratory investigations were aimed at excluding the presence of an infectious, 
inflammatory autoimmune process or coagulopathy. An extensive serological 
evaluation for HSV, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, mumps, 
measles, influenza, parainfluenza, rubella, chlamydia and syphilis was performed on 
paired blood samples and a nasopharyngeal swab or aspirate. Consulting specialists 
for ophthalmology and internal medicine were asked to exclude Cogan's syndrome 
and systemic disease, respectively. After diagnostic samples were taken, a provisional 
diagnosis ofiSSHL was made and treatment was started. In cases where a cause of the 




Chapter 2 is a literature review of the aetiology and treatment of Idiopathic Sudden 
Sensorineural Hearing Loss (ISSHL). 
Chapter3 
In chapter 3 we present a pilot study in which we investigated the inner ear and 
the cochlear nerve in fresh human tissue for the presence of herpes simplex virus, 
cytomegalovirus and varicella zoster virus using Polymerase Chain Reaction (PCR). 
Chapter4 
Presents the results of a prospective, randomized, double-blind clinical trial comparing 
a combination of prednisone and acyclovir with the standard prednisone dose in the 
treatment of ISSHL. 
Chapter5 
A pilot study is presented which assesses the bioavailability of a new 50 mg 
dexamethasone tablet for use in high-dose pulse therapy. This was done in co­
operation with the departments of Dermatology and Otorhinolaryngology within the 
University Medical Centre Groningen. Pulse therapy is an established treatment in 
pemphigus vulgaris where its aim is to reduce the daily dose of glucocorticoids, thus 
limiting the hazards of continuous long-term steroid intake. 
Chapter6 
Once the safety and bioavailability of the new 50 mg dexamethasone tablet had been 
established it was used in a new trial. A prospective, randomized, double-blind, multi­
center clinical trial was set up to evaluate this new therapy in the treatment of patients 
with ISSHL. It compared pulse therapy with standard dose prednisone. 
Chapter7 
The results and conclusion of this thesis are summarized in English. 
ChapterS 




(1) De Kleyn A. Sudden complete or partial loss of function of the octavus system in apparently normal 
persons. Acta Otolaryngol (Stockh) 32, 407-429. I-I-I944. 
(2) Marrox DE, Simmons FB. Narural history of sudden sensorineural hearing loss. Ann Otol Rhino/ 
Laryngol. I977 Jul;86(4 Pt I) :463-480. 
(3) Rabinstein A, Jerry J, Saraf-Lavi E, Sklar E, Bradley WG. Sudden sensorineural hearing loss 
associated with herpes simplex virus type I infection. N�rology. 200I Feb 27;56(4):57I-572. 
(4) Suckfull M. Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised 
multicenrre trial. Lanm. 2002 Dec 7;360(9348):I8II-I8I7. 
(5) Harris JP, Ryan AF. Immunobiology of the inner ear. Am j Otolaryngol. I984 Nov;5(6):4I8-425. 
(6) Stokroos RJ, Albers FW. Therapy of idiopathic sudden sensorineural hearing loss. A review of the 
literarure. Acta Otorhinolaryngol Btlg. I996;50( I): 77-84. 
(7) Stokroos RJ. Idiopathic Sudden Sensorineural Hearing Loss I997. 
1 3  

CHAPTER2 




Idiopathic sudden sensorineural hearing loss (ISSHL),  otherwise known as sudden 
deafness, is usually characterized in the literature by sensorineural hearing loss of 30 
dB or more over at least 3 contiguous audiometric frequencies that develops over 
a period ranging from a few hours to three days in otherwise normally hearing, 
healthy individuals1• It affects between 5 and 20 persons per 1 00,000 annually 2• 
The hearing loss is frequently associated with vestibular disturbances, tinnitus and a 
pressure sensation in the ear. Most studies report some spontaneous recovery in 45-
65% of patients; however, only a small number of patients will recover their hearing 
to functional levels 3.6. Although sudden deafness is a well-recognized condition, no 
standard definition or treatment protocol has been accepted. In addition, despite 
extensive evaluation, an aetiology can only be found in 1 0-1 5% of patients 7• Few 
dues arise from the history, physical examination and audiometric testing, which are 
the minimal elements of clinical assessment. 
Sudden hearing loss can be caused by trauma, systemic infectious diseases, neoplasia, 
autoimmune disease, vascular disturbances, and neurodegenerative disorders. Trauma 
such as temporal bone fracture, acoustic blast injury, barotrauma, or stapes surgery 
can cause sudden hearing loss. Infections due to viruses such as mumps, rubella and 
herpes viruses head the differential diagnosis list. Other infections such as syphilis, 
toxoplasmosis, and Lyme disease can also present as sudden hearing loss 8• Neoplasms 
of the temporal bone, internal auditory meatus, or posterior fossa should always be 
considered as a possible diagnosis. The acoustic schwannoma, a benign tumour of 
the eighth cranial nerve in the internal auditory meatus, can account for 1%-2% of 
sudden hearing loss 9• 
Table 1 lists known causes of sudden sensorineural hearing loss at this moment. These 
account for 1 0- 1 5% of cases of sudden hearing loss. 
In the remaining 85%-90% the cause is never identified and thus the term idiopathic 
is used; Idiopathic sudden sensorineural hearing loss. 
The different pathophysiological theories of ISSHL are described in the next section. 
As can be expected with many different theories about aetiology, the treatment options 
of ISSHL are numerous. The most important of these will be discussed in the section 
"treatment". In the conclusion, the aetiology and treatment will be put in perspective 
and our hypotheses, upon which our clinical trials are based, will be presented. 
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AETIOLOGY 
The aetiology of ISSHL remains obscure. Disturbances in the microcirculation 10, 
viral infections 1 1 •  12, cochlear membrane ruptures 13• 1 4  and immunopathological 15 
processes or a combination of such mechanisms 3 have all been hypothesized as causes 
of ISSHL. The above mentioned causes will be discussed in more detail. 
Disturbances in the microcirculation 
The vascular theories of ISSHL describe a spectrum of supposed alterations at 
the capillary and microvascular level. They include embolism, bloodsludging, 
hypercoagulability, vasospasm, intracochlear hemorrhage, arteriosclerosis, systemic 
vascular disease and connective tissue disorders. 
In many patients, the clinical picture of ISSHL is similar to that of other vascular 
diseases such as cerebral insult, myocardial infarction or retinal ischemia. The sudden 
incidence of the hearing loss strongly suggests a vascular insult. 
Vascular disturbances can cause sudden hearing loss and it has been reported after open 
heart surgery 16 and unstable angina 1 7• Hypercoagulability (an increased tendency of 
blood to clot) can also cause sudden hearing loss. lntracochlear hemorrhage can lead 
to sudden hearing loss and has been described for diseases such as Waldenstrom's 
macroglobulineamia, leukaemia, and carcinomatosis 1 8• 
In animal experiments cochlear microcirculation is sensitive to changes and even 
limited impairment of perfusion leads to immediate loss of function of the organ of 
Corti 19• The labyrinthic artery, a functional end artery, supplies the vestibulocochlear 
artery and the spiralis modiolic artery. These in turn supply the cochlea and the 
vestibular organ as an end organ. Shunting from the periphery cannot compensate for 
disturbances of regional blood flow in the inner ear. 
Fisch et al. 20, using a polarographic method, measured the oxygen tension in the 
perilymph, first in cats and later in humans. They applied this technique to patients 
with ISSHL and discovered that the perilymphatic oxygen tension was decreased 
by 30% in patients with ISSHL versus normal subjects and who also responded to 
carbogen inhalation (a means of increasing perilymphatic oxygenation 21• In patients 
with slowly progressive hearing loss normal values of perilymphatic oxygenation were 
found and a low response to carbogen inhalation. They conclude that there was a 
strong vascular component to ISSHL. In a prospective randomized study they found 
that carbogen inhalation yielded significantly better results that intravenous infusion 
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of papaverine and low molecular dextran. They recommend carbogen inhalation as an 
effective non-invasive treatment for ISSHL 21 .When 16  cases ofiSSHL were compared 
to 32 matched controls, Ciuffetti et al. 22 found distu rbances in microcirculatory blood 
flow measured by whole blood fl terability and felt that this was linked to ISSHL in 
humans. Whether vascular risk factors indeed play a role in ISSHL is still u nclear 23• 24• 
Ohinata et al. studied blood viscosity and plasma viscosity and found significant 
higher viscosity in patients with sudden deafness compared to a control group25• 
Chronic sensorineural hearing loss has been associated with whole-blood viscosity 26 
and raised serum cholesterol has been associated with the development of noise­
induced hearing loss 27• 28• Therefore, rh eo logic factors can play a role in (sudden) 
hearing loss. Fibrinogen is a large glycoprotein (340 kDa) that defines rheological 
properties of whole blood by increasing plasma viscosity and inducing aggregation of 
erythrocytes, thrombocytes and leucocytes. Raised fibrinogen is also thought to be a 
possible cause of iSSHL 29• 
In vascular disease such as cerebral stroke, infarction or myocardial infarction, 
fibrinogen is a well-established risk factor 30• In a study by Marcucci et al. 3 1 independent 
thrombophilic risk factors for ISSHL were identified. Their preliminary data suggests 
that hypercholesterolemia, hyperhomocysteinemia, elevated plasminogin activator 
inhibitor- I and anticardiolipin antibodies are associated with ISSHL, and indirectly 
support the hypothesis of a vascular component in the pathogenesis of ISSHL. 
Running counter to this theory is that experimentally induced hearing losses of vascular 
origin are predominantly irreversible, which contrasts with the natural history ofiSSHL. 
Fibrosis and ossification of the cochlea reported after experimentally produced impaired 
blood supply or by known infarction of the cochlea were not found in post-mortem 
temporal bone examination or by imaging techniques in patients with ISSHL 32-3 4• 
In a recent histopathological study of temporal bones by Merchant et al 15 they fou nd 
the hallmark of a vascular insult to the cochlea, deposition of connective tissue and 
bone, in one of their 1 7  studied ears, and in a literature search was reported twice 
in 27 ears. They conclude that vascular occlusion as an aetiologic event in su dden 
deafness is rare. 
Viral aetiology 
Viral infections such as measles, mumps, ru bella, CMV, Epstein Barr virus and 
herpes can cause viral cochleitis with sudden hearing loss as a result. Moreover, the 
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histories of around 30% of sudden deafness cases include infections of the upper 
respiratory tract 1 1 •  Serologic studies have shown a significantly increased rate of viral 
sero-conversion in patients with ISSHL 35• 36• Post-mortem cochlear histopathological 
changes seen in patients with ISSHL, including atrophy of the organ of Corti and 
tectorial membrane, closely resemble changes seen after viral labyrinthitis 32• A herpetic 
viral labyrinthitis, in particular, provided a histological pattern of cochlear damage 
that matched that of patients who had had ISSHL 37• Magnetic resonance imaging 
studies of the inner ear have shown labyrinth enhancement in patients with sudden 
deafness 38• Wilson 39 suggested that herpes virus  may be implicated in the aetiology of 
ISSHL by one of several mechanisms, including labyrinthitis secondary to viraemia, 
labyrinthitis or neu ritis secondary to meningitis, cranial neu ropathy, reactivation of 
a latent ganglion cell infection, or alteration of the immune system. Herpes simplex 
virus  (HSV-1 )  has been demonstrated as remaining latent in healthy human spiral 
ganglia 40• Experimentally induced HSV- 1 labyrinthitis resulted in sudden hearing 
loss in gu inea pigs and the cochlear histopathological findings closely resembled those 
seen in ISSHL 4 1 •  However, the evidence is circumstantial. Merchant et al 15 find 
that histopathological evidence is lacking. They conclude that evidence of direct viral 
invasion or infection, such as isolation of a virus from the labyrinth, demonstration 
of typical cytopathological abnormalities, demonstration of viral particles by electron 
microscopy, or identification of specific viral antigens, has yet to be fou nd. 
Cochlear membrane ruptures 
A perilymph fistula is defined as an abnormal patency between the inner and middle 
ear that allows flow of perilymph. A well accepted mechanism for fistula production 
is blunt, penetrating or barometric trauma. 
A su dden increase in pressure can rupture the inner ear membrane(s) . In an implosive 
event, elevated cerebrospinal flu id pressure by valsalva is thought to be transmitted via 
subarachnoid connections to the inner ear 42• 
The symptoms of a perilymph fistula include aural pressure, disequ ilibrium exacerbated 
by exertion, and both conductive and perceptive hearing loss. Once rupture has 
occurred, hearing loss is thought to result from either chemical or mechanical alterations 
in the different compartments in the cochlea where the sensory organs for hearing 
are located. Histopathological data is conflicting. Few cases of sudden hearing loss 
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show evidence of rupture, and congenital patencies are seen in normal patients 33•43• 
Valk et al. created an endolymphatic hydrops by repetitive microinjections of 0.5 
JlL of artificial endolymph at a rate of 50 nlls in an experimental setting in guinea 
pigs while measuring cochlear function as measured by distortion product otoacoustic 
emissions 44• 
A 'catastrophe' occurred in the inner ear when 2.5-3.5 JlL of artificial endolymph was 
injected, corresponding to 53-74% of the original volume. A rupture of Reissner 's 
membrane was then found, most often in the apical turn of the cochlea. This rupture 
had only minor effects on the endocochlear potential. The spontaneous occurrence 
of ISSHL without a history of (baro) trauma, even during sleep, makes a membrane 
rupture unlikely. 
Immunopathological processes 
Sudden deafness can be the first manifestation of systemic autoimmune diseases such 
as Cogan's syndrome, Polyarteritis nodosa or relapsing polychondritis. The hearing 
loss in autoimmune disease is usually bilateral and rapidly progressive, but it can also 
occur as a sudden hearing loss. McCabe 45 reported in 1 979 that a group of patients 
with sudden deafness responded well to immunosuppressive treatment with steroids 
and cyclophosphamide and described autoimmune inner ear disease as a clinical en­
tity. Harris 46 demonstrated the inner ear's capacity to respond to local antigenic 
challenge and produce systemic immunization. Since then ( 1 983) there has been con­
siderable investigation into the relationship between the immune system and senso­
rineural hearing loss. Ottaviani et al. 47 and Toubi et al. 48 have both found evidence 
of circulating antibodies in relation to sudden deafness, ranging from anti-epithelial 
auto antibodies, immune complexes, and production of auto antibodies to inner ear 
proteins, production of anticardiolipin antibodies and to cellular immune defects. 
Toubi et al.48 found a lack of persistence of anticardiolipin antibodies in as many as 
half of their patients which strongly suggested a transient phenomenon (e.g. viral 
infection) that triggered anticardiolipin antibody activity. Liao et al. 49 also suggest a 
virally mediated immune response causing the cochlear damage, and thus the hearing 
loss, as a possible pathophysiology for ISSHL. The immune response can provoke the 
degeneration of the organ of Corti, stria vascularis and spiral ganglion 50• 
The immune reaction in the inner ear as the cause of ISSHL is supported by a study 
by Wilson et al. 51 and Moskowitz et al. 52 in which corticosteroids had a limited but 
significantly better restorative effect on hearing than the placebo. It is possible that 
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immune-mediated inner ear disease accounts for at least some of the cases of steroid­
responsive ISSHL 53• 54• Because markers for autoimmune inner ear disease have been 
identified, further work is needed to evaluate whether auto immune disease plays a role 
in ISSHU5• 56• 
'ThEATMENT 
Since the aetiology ofiSSHL is still unknown most studies have involved a multimodal 
treatment strategy based on the assumption that one or more medication or techniques 
will reverse the hearing loss. 
This empiric strategy has the advantage that at least one effective treatment may 
be provided to the patient, but has drawbacks of obscuring the effect of any single 
treatment, as well as exposing the patient to side effects of a number of different 
treatments. Evaluation of treatments has further been hampered by the low incidence 
of ISSHL and the tendency for spontaneous hearing recovery. 
The most widely used treatments for ISSHL are vasodilators, rheological/vasoactive 
substances, anti-inflammatory medication, antiviral medication, and hyperbaric 
oxygen. Other drugs such as intravenous contrast agents, Calcium channel blockers, 
and magnesium have all been assessed in clinical studies. These treatment strategies 
will be discussed in more detail below. 
Vascular treabnents 
It has been frequently postulated that ISSHL has a vascular origin and "vascular" 
treatments have been widely used. Vasodilators increase the calibre of the blood vessels 
and thus improve blood flow whereas vasoactive/rheological substances increase flow 
through blood vessels by other mechanisms such as altering the viscosity of blood. 
Numerous treatments have been proposed to improve cochlear blood flow (CBF) 
by either vasodilatation (histamine 5, papaverine 21, carbogen inhalation 57) or by 
decreasing blood viscosity (defribinogenation therapy 58 dextran 59, pentoxifillin 60 
and LD L apheresis 10• 61• 
Intracranial blood flow possesses a strong auto-regulation that will, in most cases, 
override the effect of vasodilators 62• Therefore, vasoactive treatments may in fact 
decrease CB F. Ohlsen et al. 63 studied the topical and systemic effects of hydralazine, 
sodium nitroprusside, papaverine, nicotinic acid, verapamil and histamine in an 
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animal model. Hydralazine, histamine and nitroprusside administered topically 
increased CBE The effect systemically administered vasodilators had on CBF was 
highly variable and at times CBF was actually decreased. As a consequence, results with 
vasoactive therapies are mixed. Kronenberg et al. 59 could not prove the effectiveness of 
dextran in a double-blind randomized placebo-controlled clinical study. Dextran and 
pentoxifillin gave results no better than placebo or spontaneous recovery 60• Rahko 
and Kotti 57 compared carbogen inhalation and intravenous heparin but could not 
prove one superior to the other. The patients in the latter study, however, were not 
selected and the study was not placebo controlled. 
Other studies do report successes. In a large study by Suckfiill et al. 10 speech perception 
was significantly better after acute reduction of plasma fibrinogen and serum LDL 
using apheresis as compared to their standard treatment of prednisone, hydroxyethyl 
starch and pentoxifylline. The overall pure tone thresholds, however, were slightly but 
not significantly better in the apheresis group. 
In an uncontrolled pilot study by Ullrich et al. 61 , 80% of sudden-onset hearing loss 
patients showed complete recovery in a four-week period. They were treated with 
specific fibrinogen apheresis. Their definition of ISSHL was not very strict. What 
both studies did prove was that apheresis significantly reduces fibrinogen. 
Anti-inflammatory treabnent 
Steroids are anti-inflammatory drugs which are used to suppress inflammatory changes 
such as cellular infiltration and tissue oedema, limitations of which increase tissue 
perfusion. The specific action of steroids is unknown but they may be beneficial in 
infectious, inflammatory and immune-mediated conditions. Corticosteroids are widely 
used in the treatment of ISSHL. In spite of their wide clinical use, few randomized, 
double-blinded clinical trials are available in the treatment of ISSHL. 
Nevertheless, steroid therapy is among the few treatment methods in ISSHL to have 
been subjected to single modality, randomized prospective studies demonstrating 
effectiveness. 
Wilson et al. 51 designed a prospective, randomized, double-blind study evaluating 
steroids in the treatment of ISSHL. Sixty-seven patients were enrolled in the study: 
33 received steroids and 34 received a placebo. Fifty-two patients refused treatment 
and functioned as an untreated control group. After matching for age and vertigo, the 
steroid group achieved significantly better hearing (p = 0.0 1 7) .  Subsequently, Wilson 
reported a 78% recovery rate for patients with moderate (35-90 dB) hearing loss 
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versus 38o/o for the placebo 64• The authors conclude that given the nature of the 
hearing loss and it's susceptibility to improvement with steroid therapy lend support 
to the hypothesis that viral cochleitis is the primary cause ofiSSHL. 
Moskowitz et al. 52 conducted a prospective randomized trial , fashioned after the 
Wilson study, on 36 patients with ISSHL. It confirms the findings in the Wilson 
study. Twenty-seven patients received dexamethasone, whereas nine patients received 
a placebo. The steroid group recovered to 89o/o functional hearing levels compared 
with the placebo recovery rate of 44%. This difference was statistically significant 
(0.005 <p <0.01 ) .  Unfortunately the study was not double-blinded, which decreased 
it's internal validity. 
Fecterman et al. 5 retrospectively reviewed the charts of 837 patients with sudden 
sensorineural hearing loss eo evaluate the prognostic value of specific clinical parameters 
and the effectiveness of steroid and vasodilator treatments. Treatment response was 
defined by the patient's subjective response and audiological criteria. Patients who 
were created with steroids, vasodilators or both were more likely to improve. However, 
the best rate of recovery was 62.9% in the steroid/vasodilator group. Patients who 
improved had worse initial pure tone averages than did those who did not improve. 
In addition, younger patients, those with poorer initial speech discrimination scores, 
worse initial thresholds at 4000 Hz and a greater number of treatments were more 
likely to improve. 
The mechanism of steroid action in the inner ear remains open to speculation; they 
increase the microvascular blood flow in the cochlea, reduce the inflammation and 
the onset of endolymfatic hydrops 65. Rarey and Curtis 66 reported the presence of 
glucocorticoid receptors in the spiral ligament and in other parts of the inner ear. 
Hearing improvement following administration of glucocorticoids might be due to 
( 1 )  their anti-inflammatory effect; (2) increasing stria vascularis synthesis of Na+­
K+ adenosine triphosphatase, which decreases vascular permeability (particularly to 
circulating immune mediators) ; and (3) increasing cochlear expression of aquaporin 
1 and 3 67• 
In 2006 the Cochrane collaboration published it's review for "Steroids for idiopathic 
sudden sensorineural hearing loss" 68• They found only two randomized controlled 
trials addressing the effectiveness and safety profile ofiSSHL which met their minimum 
criteria. The included studies were of poor quality and contained relatively low number 
of patients. Of the 5 1 6  abstracts retrieved from the search, 486 articles were excluded 
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as they did not focus on ISSHL; the treatment effect was not targeted primarily on 
steroids or the steroids were used as control for the comparison of other treatments. Of 
the remaining 30 studies only two were included in the review. The rest were excluded 
as they were non-randomised and non-controlled studies. The two studies were by 
Cinamon et al.6 and Wilson et al. 5 1• In the Cinamon study no difference in treatment 
was found between placebo and steroids whereas in the Wilson study a positive effect 
of steroids was found. The Cochrane collaboration concludes that there is no good 
evidence to suggest the effectiveness or the lack of effectiveness of steroids in the 
treatment of ISSHL. The incidence of side effects and the cost of steroid treatment 
in ISSHL still remain to be determined. They acknowledge however, that the low 
incidence and high spontaneous recovery significantly impedes methodological sound 
studies with large enough patients groups to accurately determine the effectiveness of 
steroids. 
Antiviral treatment 
Hughes et al. 69 have suggested the use of aciclovir in the treatment regimen for ISSHL 
but Stokroos et al 70• and Tucci et al. 71 could not prove the effectiveness of aciclovir or 
valaciclovir as adjuvant therapy to prednisone in the treatment of ISSHL. Interferon 
(IFN) has been reported as being beneficial in the treatment of ISSHL. Kanemaru 
et al. 72 administered IFN-alpha, low-molecular-weight dextran and steroids to 42 
patients with ISSHL. Complete recovery was found in 27 patients (64.3%). This is 
comparable to the spontaneous recovery rates of 45-65% as reported by Mattox and 
Simmons 1 1• However, IFN has recently been reported as potentially ototoxic and had 
serious side effects 73• Therefore the effi cacy of IFN in the treatment of ISSHL is still 
unproven. 
lntratympanic steroid treatment 
lntratympanic therapy can be defined as delivering a medication to the round 
window membrane with uptake into the inner ear. Advantages of this technique are 
( 1 )  the diseased ear is treated directly without affecting the entire body, (2) a higher 
concentration of medication can be obtained, (3) systemic side effects of the drug 
are prevented 74• It is based on the findings from animal studies that demonstrate 
steroid uptake through the round window membrane into the cochlea when the drug 
is instilled into the middle ear 75• There are several means of delivering steroids to the 
round window membrane: single intratympanic (IT) injections, repeated IT injections 
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or insertion of sustained release vehicles through the tympanic membrane. 
IT offers the ability to achieve higher inner ear drug concentrations, freedom from 
adverse systemic effects (of steroids) and can be used in patients for whom systemic 
steroids are contraindicated. 
The procedure, however, is not risk free. Known adverse effects include tympanic 
membrane perforation, increased dizziness and possible compromise of residual 
hearing 76• 
lntratympanic pharmacotherapy was first used by Schuknecht in 1956 n when 
aminoglycosides were installed for the treatment of vertigo in Menie re's Disease. 
Since that time, intra tympanic applications of other agents have been used for various 
other inner ear disorders. These agents include corticosteroids, local anaesthetics, 
otoprotective drugs and other antibiotics 78• 
There is now a large body of work demonstrating intratympanic steroid uptake 
through the round window membrane in animal models 79-81• Nakashima et al. 82 
recently visualized and followed intratympanically administered drugs into the inner 
ear with the use of intratympanic injections with diluted Gadolinium and a MRI­
scan. Although much of the literature is focused on the application of intratympanic 
steroid therapy for the treatment of Menie re's disease with intractable vertigo 83• 84, 
this treatment option is receiving broader indications. In particular, treatment of 
autoimmune inner ear disease, sudden hearing loss and tinnitus has been reviewed. 
Slattery et al. 85 conducted an open-label clinical trial ofintratympanic steroid injection 
for ISSHL in subjects who failed oral steroid therapy. Twenty subjects received 4 
injections within a two-week period. Hearing, dizziness and tinnitus were evaluated. 
A total of 1 1  subjects (55%) clinically improved in either pure tone audiogram (PTA) 
or speech discrimination scores (SDS) at one month after treatment. One patient 
improved 26 dB, exceeding 50% of baseline by 9 dB, 5 subjects experienced a 10  dB 
improvement and a total of? subjects had a clinically significant improvement in SDS 
greater than 12%. 
Herr et al. 86 also studied intratympanic steroid therapy in patients with sudden hearing 
loss as a salvage treatment. These patients were refractory to ten days of intravenous 
steroid, pentoxifylline and hydroxyethyl starch (HES) treatment. Forty consecutive 
patients participated in this prospective study. The patients were divided into three 
groups of hearing loss: ( 1 )  twenty-one patients with flat audiograms with a hearing 
loss of more than 30 dB but less than 80 dB, (2) ten patients with profound hearing 
loss of more than 100 dB and (3) nine patients with high frequency hearing loss. 
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In group 1 ,  33% patients recovered to withi n 1 0  dB of the hearing threshold of the 
unaffected ear, wi th no complete recoveries seen in groups 2 and 3. No improvement 
of more than 1 0  dB was found in 29% patients in group 1 ,  40% patients in group 2 
and 56% patients in group 3. 
They conclude that intratympanic treatment of dexamethasone/hyaluronic acid 
significantly improved hearing in a subgroup of patients. However, there were no 
control groups (placebo) ,  bli ndi ng or comparison between groups. Furthermore, the 
dividing of an already small patient population into three subgroups may not have 
been wise. 
In a review by Doyle et al. in 2004 76 of the period 1996 to 2003, they found 5 studies 
that were all retrospective case series or uncontrolled prospective cohort studies in 
which intratympanic steroids had been administered for sudden deafness. In 2 studies 
even patients with various other inner ear maladies were included. The intratympanic 
treatment was found to be most promising as salvage therapy after a fai led course of 
steroids. However, the quality of the studies was insufficient to answer the question of 
the efficacy of the treatment. 
It would seem that intratympanic steroid therapy as a salvage treatment in patients 
with ISSHL infractory to systemic steroid treatment is an option. It is not advised as 
a primary treatment option. The lack of quality of the available studies make i t  all the 
more urgent to start prospective randomized blind clinical trials before any definitive 
conclusions can be drawn. 
Hyperbaric oxygen therapy 
In 2005 the Cochrane collaboration published its review regarding hyperbaric oxygen 
therapy (HBOT) for idiopathic sudden sensorineural hearing loss and tinnitus 87• It 
concluded that on the basis of the five selected studies there is limited evidence from 
methodologically poor studies that hyperbaric oxygen therapy improves hearing in 
patients with ISSHL who are treated wi thin two weeks of their hearing loss. There 
is no evidence that any improvement is functionally important. They conclude that 
routine use of HBOT in ISSHL could not be justified. 
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Shotgun (combination) and miscellaneous therapy 
The idea behind shotg un therapy is that treatments are given for several etiolog ies, 
hoping that one or more will work. Usually a combination of vasoactive treatments 
and steroids are given. Wilkins et al. 88 treated 109 patients with idiopathic sudden 
hearing loss with a reg imen that included dextran, histamine, Hypaque (Winthrop 
Pharm), diuretics, steroids, vasodilators and carbog en inhalation. Thirty-three patients 
received the entire protocol and 76 patients received most, but not all, of the protocol 
drugs. There was no statistically sig nificant difference in outcome between patients 
treated with the complete protocol and those who received only part of the protocol. 
Furthermore there was no difference between those patients receiving and not receiving 
treatment. These results suggest that this " shotg un" approach for treatment of sudden 
hearing loss offers no better outcome than is reported in the literature for spontaneous 
recovery. 
Redleaf et al. 89 performed a retrospective chart analysis on 39 patients treated with a 
combination of diatrozide and dextran. Diatrozide (Hypaque) , a triodobenzoic acid 
derivative, is thought to interact with the epithelium of stria vascularis and preserve 
generation of endocochlear potentials. All of the patients were treated for five to seven 
days with daily injections of diatrozide and dextran. Of these patients, 64% improved 
their pure tone averag es, speech reception thresholds and speech discrimination levels 
while receiving treatment. They found no difference in recovery between patients 
treated within seven days and those treated more than seven days after onset of the 
sudden hearing loss. Because of the lack of control g roup no conclusions can be 
drawn, but there seemed to be some effect in a subpopulation for which intravenous 
contrast is efficacious. They suggest further trials with diatrozide and dextran. Emmett 
and Shea 90 also used a combination of carbogen, intravenous histamine, steroids, 
diuretics, low-salt diet and Hypaque to treat ISSHL. Again there was no control group 
of untreated patients. The results in this highly selective group treated within one 
month of onset, with no vertig o and incomplete hearing loss showed an 80% rate of 
recovery. No statisti cal conclusions could be drawn from this study. 
Diatrizoate meglumine (Hypaque; Winthrop Pharm, New York, NY, U.S.A.89• 90 and 
xanthinolnictone (Compalamine) 91 have also been used to treat ISSHL. Morimitzu92 
first reported the use of diatrizoate in ISSHL and subsequently compared the results 
of 60 treated patients with the results in the Japanese reg istry. He found statistically 
sig nificant improvement (37% complete recovery) but the treated g roup did not have 
vertigo and no untreated control was used. 
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Calcium channel blockers have vasodilatory and spasmolytic action on cerebral 
vessels. Calcium channel blockers also lower intracellular calcium and can reduce the 
adenosine triphosphate use in  the damaged cells, thus protecting hypoxi c sensory cells. 
Studies in European li terature show no significant benefit from the use of calcium 
channel blockers i n  the management of iSSHL 93• 
In a prospective, randomized, double-blind placebo-controlled clinical trial, Nageris 
et al. 93 found that in 28 patients with ISSHL, magnesium as adjuvant to prednisone 
therapy improved the proportion of patients with hearing recovery as well as a significant 
mean i mprovement of hearing recovery. Magnesium is a critical cation in i ntracellular 
metabolism and energy production and consumption. It also serves as a cofactor i n  
enzymatic processes involved in protein construction and aerobic phosphorylation. 
There is a close functi onal relationship between magnesium concentration and 
calci um metabolism. 
Vitami ns are believed to reduce free radicals that are toxi c to sensory end-organs, such 
as the i nner ear. Several vitami ns in combination with vasodilator therapy have been 
used in the past. Studies of ginkgo biloba extract have shown no significant efficacy in 
the management of iSSHL 94• 
CONCLUSION 
ISSHL remains a baffling and controversial phenomenon. A universal definition 
would be an important step in creating a clear picture of this disease. The Cochrane 
collaboration uses a definition that should become the universal defini tion: sudden 
sensorineural heari ng loss is an abrupt or rapidly progressive hearing loss of at least 30 
dB in at least three contiguous frequencies over a period of no more than three days. 
Idiopathic sudden sensorineural hearing loss (ISSHL) i s  sudden hearing loss where 
clinical assessment fails to reveal a cause. 
The different theories discussed in this chapter are disturbances in the microcirculation, 
viral infecti ons, cochlear membrane ruptures, immunopathological processes or a 
combination of these mechanisms. Maybe ISSHL is a symptom rather than a distinct 
disease with different causes. The clinical picture ofiSSHL however, gives no clue that 
allows us to differentiate between different underlyi ng pathophysiological mechanisms . .  
The inner ear is  well protected and diagnostic samples are contraindi cated because of 
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the high percentage of spontaneous recovery. However, in 10- 1 5% of cases, sudden 
hearing loss is caused by a known pathological mechanism. Therefore, a complete 
history and medical evaluation remain necessary, complete with audiological and 
vestibular tests, laboratory evaluation and MRI of the cerebellopontine angle. Most 
studies report a spontaneous recovery of 45-65%. Until now nobody has been able to 
predict who will recover and how large that recovery will be. Furthermore, recovery 
is reportedly influenced by factors such as time of presentation, hearing loss levels, 
and accompanying factors as vertigo and tinnitus. All these factors must be taken into 
account when comparing treatment results between different studies. 
The sudden loss of hearing strongly resembles other vascular diseases such as cerebral 
insult, myocardial infarction or retinal ischemia. When Fisch et al 20 discovered 
lowered perilymphatic oxygen tension in patients with ISSHL as compared to control 
subjects the vascular theory was born. Since then a whole spectrum of changes in 
the blood supply to the cochlea have been proposed as aetiology for ISSHL. It is 
extremely unlikely that an occlusion of the labyrinthic artery, by any mechanism, is 
the cause of ISSHL. The irreversibility of the hearing loss as a result and the absence 
of cochlear ossification do not fit the clinical picture in ISSHL. This does not imply 
that disturbances in the microcirculation do not play a role in ISSHL. 
With the exception of carbogen, systemic vasodilator therapy does not appear to 
actually increase cochlear blood flow and may, in fact, decrease the blood flow to 
the inner ear 21.  63• Changing the rheologic properties of blood by fibrinogen/LDL 
apheresis can reduce the blood viscosity by about 20% Although some studies have 
shown promising results, no randomized, large, controlled, single-modality blinded 
studies have reported improved hearing levels when using vasoactive therapy. The 
theory of disturbances in the microcirculation continues to have many followers. 
Viral infections can cause sudden hearing loss and post mortem histolopathologic 
studies have shown remarkable resemblances between ISSHL and virally induced 
hearing loss. A labyrinthitis is thought to be the cause of the hearing loss. The viral 
theory has undergone a modification since the inner ear was shown to be capable of a 
response to local antigenic challenge and produce systemic immunisation 13• 
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There seems to be a relationship between the immune system and sensorineural 
hearing loss. In an assimilation of the viral theory and the immunologic theory it 
is thought that a (virally) induced labyrinthitis starts an immune challenge to the 
inner ear which in turn leads to hearing loss. It is the immune reaction that does the 
damage to the inner ear. Absent virus particles or infection in the inner ear as seen by 
Merchant et al 15 can now be explained. 
Membrane ruptures are extremely unlikely as a cause of ISSHL, therefore this theory 
is of academic interest. 
Several single-modality, prospective studies of steroids have demonstrated statistically 
significant improvement in recovery for ISSHL35 · 5 1 • 52• 
However, other studies have questioned the effectiveness of steroids 3• 6• 68• Although 
treatment with steroids appears to have the greatest degree of scientific support, further 
study is required. This is confirmed by a review done by the Cochrane collaboration 
in 2006 68• They conclude, on the basis of just two trials that satisfied their inclusion 
criteria, that 'the value of steroids in the treatment of idiopathic sudden sensorineural 
hearing loss remains unclear since the evidence obtained from randomised controlled 
trials are contradictory in outcome, in part because the studies are based upon too 
small a number of patients'. Unfortunately, other than these two studies, there is an 
almost universal lack of proper studies with adequate control groups in the literature 
on the treatment of iSSHL. 
A meta-analysis by the Cochrane group is underway to study the effects of vascular 
therapies. 
No universally accepted treatment for ISSHL exists. The treatment chosen for ISSHL 
is dependent on the theory of choice which probably is more culturally defined than 
evidence based. We feel that a (virally) induced immune reaction in the inner ear is the 
main cause of ISSHL and we treat it accordingly. In the following chapters two trials 
are presented in which the treatment of ISSHL is systematically evaluated. The first 
trial concentrates on treating a possible virus infection; the second trial concentrates 
on the immune reaction, as a cause of the hearing loss. 
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After 60 years of research, the aetiology and treatment of ISSHL is still open to 
debate. It even remains uncertain whether ISSHL is a symptom with a multifactorial 
aetiology or a disease entity in itsel£ Perhaps it would be best to return to basics 
and methodically test the different hypotheses, while always testing treatment options 
against a placebo. Unfortunately, however, the low incidence of ISSHL hampers the 
inclusion of adequate numbers of patients, having a placebo in a control arm it will be 
that much more difficult to enrol enough patients into the study. 
The treatment of ISSHL is best studied in large, controlled, multicenter treatment 
protocols. We would also strongly urge the reporting of actual hearing levels in results 
and the abandonment of multi-drug therapy protocols. 
Table I. Differential Diagnoses in Sudden Deafness 
I .  Inflammatory 
1 . 1  Viral 
1 .2 Bacterial 
2. Vascular 
3. Hematological 
3 1  
1 . 1  - Mumps 
- Rubella 
- Measles 
- Parvovirus B 19  
- Cytomegalovirus 
- Infectious mononucleosis 
- Herpes simplex 
- Varicella-zoster 
- HIV 
1 .2 - Acute otitis media 
- Typhoid fever 
- Mycoplasma pneumoniae 
- Chlamydia trachomatis 
- Chlamydia pneumoniae 
- Chlamydophila psittaci 
- Ehrlichiosis 





2. 1 Stroke 
2.2 Recent heart surgery 
2.3 Buerger's disease 
2.4 Sickle cell disease 
3.1  Leukaemia 
3.2 - Increased viscosity 




3.3 Coagulation disorder 
Chapter2 
4. Connective tissue disorders 
5. Metabolic disorder 
7. Ototoxic drugs 
8. Traumatic 
9. Meniere's disease 
10. Meningitis 
1 1 . Multiple sclerosis 
1 2. Sarcoidosis 
1 3. Friedrich's ataxia 
14. Amyotrophic lateral sclerosis 
1 5. Vogt-Kayanagi-Harada syndrome 
1 6. Tumours 
17. Central deafness 
1 8. Feigned hearing loss 
4.1  SLE 
4.2 Polyarteritis Nodosa 
4.3 Cogan's syndrome 
4.4 Wegener's granulomatosis 
4.5 Relapsing polychondritis 
4.6 Rheumatoid arthritis 
5 . 1  IDDM 
5.2 Renal f.tilure 
5.3 Renal tubular acidosis 
8.1  Head Trauma 
8.2 Barotrauma 
8.3 Acoustic Trauma 
8.4 Otological Surgery 
uveitis/alopecialvitiligo/dysacusia 
16.1  Acoustic neuroma 
1 6.2 Carcinomatous neuropathy 
16.3 Metastasis 
See relevant chapters for literature references. 
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INTRODUCTION 
Idiopathic Sudden Sensorineural Hearing Loss (ISSHL) annually occurs between 5 
-20 per 100.000 persons annually in the Netherlands and Flanders, but its aetiology 
and therapy remain subject to contradiction 1 • A viral cause was hypothesized because 
clinical observations reported a viral upper respiratory infection often preceding ISSHL 
in about 30o/o of cases 2• This led to the supposition of viral cochlear labyrinthitis to 
cause ISSHL 3• Infections by several viruses such as mumps, measles, rubella, varicella 
zoster virus, cytomegalovirus virus, Lassa virus and herpes simplex are known causes 
of acute sensorineural hearing loss 4·7• Cochlear changes in post mortem temporal 
bone histology found in ISSHL resemble those found after hearing loss associated 
with rubella and mumps 8 Such changes are also found in experimentally induced 
labyrinthitis. 
Reports of seroconversion of herpes antibody titers in ISSHL and the presence of 
latent neurotropic herpes viruses in the spiral ganglia of asymptomatic individuals, 
have drawn attention to the possible role of this virus family in causing ISSHL 9-1 1 • 
This brings up another possible mechanism: latent virus infection of the ear and its 
reactivation. According to current concepts of virology it is apparent that the group 
of herpes viruses such as herpes simplex virus type- 1 (HSV-1 ) ,  HSV-2, varicella zoster 
virus (VZV) and cytomegalovirus (CMV), all have a strong neurotropism 12• The 
HSV-1  DNA and the HSV-2 DNA have been detected in post mortem human spiral 
ganglia, as well in geniculate, trigeminal and vestibular ganglia 1 1 •  13•16• Both viruses 
initially infect and replicate in mucoepithelial cells and then travel retrogradely along 
sensory nerves to the sensory ganglia where latency is established. A recurrence can 
be activated through various stimuli (e.g. stress, trauma, fever or sunlight) . In this 
event the virus travels back down the nerve causing lesions to develop at the site 
innervated by this nerve 17• VZV has similar characteristics and latent VZV has been 
demonstrated in the human trigeminal, thoracic and geniculate ganglia 18• Finally, 
it has been speculated that CMV-Iabyrinthitis may not solely be associated with 
congenital infections but also with the reactivation of a latent virus later in life 1 9• 
So far, HSV-1 and HSV-2 have been detected post mortem in spiral ganglia and in 
animal models. In this pilot study, specimens from fresh nervous tissue of the inner ear 
were taken during operations in which access had to be gained to the cerebellopontine 
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angle. Samples of the inner ear were then analyzed to detect HSV-1 ,  HSV-2, VZV 
and CMV using the polymerase chain reaction analysis (PCR). Under the hypothesis 
that ISSHL is the result of a reactivation of a herpes family virus, latent virus should 
be present and detectable in a proportion of the "normal" population. 
MATERIALS AND METHODS 
Patients and specimens 
This study is based on 2 1  patients with need for neuro-otologic surgery in which the 
inner ear was sacrificed. No history of ISSHL or recent herpes infection was present. 
All patients signed an informed consent before inclusion in the study. During surgery, 
samples from different parts of the inner ear and neural tissue were collected. Before 
the modiolus was resected, 0.2 ml of perilymphatic fluid was collected. The nervus 
cochlearis (N VII) was located and a clinical specimen of endoneuria! fluid was 
collected by absorbing it with a small sterilized surgical sponge immediately after the 
epineural sheath was incised. A small sample of the nerve itself was then collected. All 
specimens including the modiolus were immediately stored at -80oC and remained 
stored at that temperature until PCR analysis was done. Peri-operatively 1 0  ml of 
blood was collected. The serum was analyzed for HSV-IgG, CMV-IgG and VZV­
IgG. 
During all procedures care was taken not to contaminate the samples. 
Laboratory Methods 
The serum was analyzed for HSV-IgG, CMV-IgG and VZV-IgG. 
The PCR analysis was done at the Laboratory for Infectious diseases, Groningen, 
using a well established DNA-extraction method and using routine "in-house" PCR 
tests. 
REsULTS 
In the period 1999-2001 2 1  patients were enlisted in the study. All patients underwent 
surgery to the temporal bone in which the inner ear was sacrificed. There were 1 5  
males and the average age was 5 7  years (range 30-74). Fourteen patients were operated 
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because of a vestibularis schwannoma, two patients underwent a petrosectomy, one 
patient had a N. Facialis schwannoma, one patient had cholesteatoma, one patient 
with a glomus jugulare type c2, one patient with an adenocarcinoma of the parotid 
gland, and one patient with an osteoma. 
Sample collection 
It proved more difficult than anticipated to collect all required samples. Especially 
endoneuria! fluid and ganglion spirale were particularly difficult to obtain. Only 1 1  
endoneuria! fluid samples and 14  ganglion spirale samples could be collected and 
tested. perilymph (21 samples), ganglion vestibulare (21 samples) and n. cochlearis 
( 19  samples) were more easily collected. 
Serum samples 
Of the 21  patients, 1 8  were positive for HSV-IgG and VZV-IgG, one was negative 
for both and two were not tested. CMV serology was different. Seven patients had a 
positive CMV-IgG, eleven were negative and three were not tested. In short almost all 
patients were positive for HSV and VZV, but only 40% were positive for CMY. 
PCR-analysis 
Two patients had a positive CMV-PCR and one patient had a dubious positive CMV­
PCR. The CMV-PCR was positive in the spiral ganglion and perilymph respectively. 
The dubious positive was located in the perilymph. The two patients with a positive 
CMV-PCR had a dubious positive VZV-PCR in the n. cochlearis. All other samples 
were negative. 
An inverse relationship was noted for serology and PCR tests concerning CMY. All 
patients with a positive IgG for CMV were negative in their PCR tests. Of the 1 1  
negative CMV-IgG samples three had a positive (or dubious) CMV-PCR. 
DISCUSSION 
In our patient group we detected only two positive PCR-reactions for CMV and three 
dubious positives for VZV (n=2) and CMV (n= 1 ) .  Furthermore, it proved impossible 
to collect all required samples. This is in contrast with results from the literature where 
Fukuda et al. 1 1  Murakami et al. 2° Furuta et al. 14 21 and Schulz et al. 22 could collect 
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and detect herpes family viruses with PCR in spiral ganglia, endoneuria! fluid and 
vestibular ganglia with relative ease. 
Worldwide, more than 90 percent of people are seropositive for HSV-1 by their fourth 
decade of life, especially those of lower socioeconomic groups 23• This is corroborated 
by our own findings that 1 8  out of 21  patients had a positive IgG for HSV. 
Not one of our PCR samples was positive for HSV. Although the failure to detect a 
herpes simplex virus in our series and the very low incidence ofVZV and CMV was 
unexpected, some methodological limitations are apparent which might explain our 
results in part. 
We collected samples from live patients and not from cadaver dissection as is the case 
in the literature. This is probably the major factor which influenced all aspects of 
our sampling. Radical excision of the ganglion spirale and vestibulare is not the same 
during surgery when compared to cadaver dissection. This influenced the volume of 
the samples, which was very small. The small volume influenced the sensitivity of the 
tests and it is possible that not enough virus particles were present in the samples for 
detection. 
The study was set up as a pilot study to see if it was possible to collect samples 
intraoperatively and to detect virus particles in these samples. No negative controles 
were collected during sampling. This might have influenced the internal validity of 
the study. All PCR tests were performed with positive and negative controls. 
The analysis by PCR was done after all samples had been collected. This had a logistical 
and financial reason. It is much easier and cheaper to perform a " batch" analysis than 
to analyse each sample separately. 
The combination of sample collection from live patients and collective PCR analysis 
meant that after the results came in, there was no possibility of changing our methods 
to improve our success rate. 
The positive CMV-PCR combined with negative CMV-IgG in three patients is 
noteworthy. These results can be explained by a possible reactivation of a latent CMV­
infection before the formation (or reappearance) of antibodies against CMY. Two of 
the three patients were fighting an infection (cholesteatoma and osteoma) and this 
could have lowered the cellulair immunity, making them more susceptible to a CMV­
infection. 
In this study we failed to identify a herpes family virus in the inner ear of unselected 
patients and failed to find additional support for the theory of a reactivation of a 
latent herpes simplex infection in the inner ear as a cause of ISSHL. Despite this 
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study we feel that the clinical picture of sudden deafness closely resembles a sudden 
inflammatory "disease" and that a latent herpes infection remains a good candidate 
as a triggering mechanism. The high prevalence of herpes viruses in the general 
population is undisputed and therefore our failure to detect these viruses is probably 
due to methodological issues rather than absent virus. 
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INTRODUCTION 
Idiopathic Sudden Sensorineural Hearing Loss (ISSHL) is characterized by 
sensorineural hearing impairment or deafness, which develops during a very short 
period in otherwise normally hearing persons. The hearing loss is frequently associated 
with vestibular disturbances, tinnitus and a pressure sensation in the ear. 
In a majority of the cases ISSHL is unilateral but infrequently both ears are involved. 
Spontaneous hearing recovery is reported in 45-65% of the cases, although in a small 
majority of the cases hearing will recover to functional levels1 • 
Although the precise etiology ofiSSHL is still unknown Van Dishoeck first suggested 
a viral involvement in 1 957, when he reported observations of an upper respiratory 
infection preceding the hearing loss 2• This hypothesis is supported by reports of 
seroconversion of viral antibody titers for several viruses in patients with ISSHL 3• 
MRI studies of the inner ear have shown labyrinth enhancement in patients with 
ISSHL 4• Post-mortem cochlear histopathological changes seen in ISSHL patients 
closely resemble changes seen after viral labyrinthitis 1 ;5 • Especially a herpetic viral 
labyrinthitis provided a matching histopathological pattern of cochlear damage 
when compared to patients having suffered from ISSHL 6• Herpes simplex type 1 
(HSV-1 )  has been demonstrated to remain latent in healthy human spiral ganglia 7• 
Experimentally induced HSV- 1  labyrinthitis resulted in sudden hearing loss in guinea 
pigs and cochlear histopathology closely resembled cochlear histopathology seen in 
ISSHL 8• 
As a result of these findings we have hypothesized that ISSHL is caused by a reactivation 
of a subclinical labyrinthine infection, possibly by HSV- 1 .  
Therapy for ISSHL still remains unknown even though many drugs have been tried, 
ranging from vasodilators, plasma expanders, intravenous contrast agents, carbogen 
inhalation, corticosteroids or all of them together as "shotgun" therapy 9• Treatments 
given depended on the believed cause of ISSHL or directed at all hypothesized causes 
ofiSSHL. The only treatment that has proven more effective than placebo is the early 
application of corticosteroids 10;1 1• Cochlear damage seemed to be limited by the anti­
inflammatory properties of the corticosteroids. 
In experimentally induced HSV-1  labyrinthitis a combination therapy consisting 
of aciclovir and corticosteroids proved more effective than either therapy alone in 
limiting cochlear damage and achieving earlier recovery 8• This combination therapy 
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is also favored in other herpetic infections 1 2;13 but has not been reported in ISSHL. 
After 14 days it is clinically accepted that the viral replication stage has ended and the 
addition of aciclovir to steroids is no longer effective. 
In this study we evaluated the treatment of iSSHL using aciclovir and corticosteroids 
versus corticosteroids alone in a prospective, double-blind, randomized clinical trial. 
The aim of the study and the preliminary data of the study evaluating the combination 
of antiviral treatment with acyclovir and corticosteroids in the treatment of ISSHL 
were published elsewhere 14• 
PATIENTS AND METHODS 
In- and exclusion criteria 
Patients participating in the trial met the following criteria ( 1 )  sensorineural hearing 
loss of unknown etiology; (2) hearing loss of at least 30 dB HL for three subsequent 
one octave steps in frequency in the standard pure tone audiogram; (3) blank 
otological history; (4) hearing loss occurring within 24 hours. Exclusion criteria were 
( 1 )  hearing loss occurring more than 14 days ago; (2) contraindications for the use of 
either prednisolone or acyclovir. 
Diagnostic protocol 
In order to exclude a known cause of hearing loss, the patients entered a diagnostic 
protocol that included complete history and physical examination, audiological and 
vestibular tests, MRI of the temporal bone and laboratory work-up. Evaluation and 
treatment of sudden sensorineural hearing loss was considered a medical urgency. 
Laboratory investigations were aimed at excluding the presence of an infectious, 
inflammatory or autoimmune process or coagulopathy. An extensive virus serological 
evaluation for HSV, VZV, CMY, Epstein-Bar, mumps, measles, influenza, 
parai nfluenza, rubella and chlamydia, was performed using pai red blood samples and 
nasopharyngeal swab or aspirate. Consults for ophthalmology and internal medicine 
were asked to exclude Cogan's Syndrome and systemic disease. After diagnostic 
samples had been taken, a provisional diagnosis of ISSHL was made and treatment 
was initiated. When a cause of sudden hearing loss could be identified later, patients 




Before participation, patients were given oral and written information about the 
study. Patients were required to sign a written informed consent, designed according 
to European Good Clinical Practice regulations, before participation in the study. 
Study design 
The study was designed as a prospective, randomized, double-blind, placebo-controlled 
clinical trial. A multicenter approach was necessary because the low incidence of 
ISSHL makes inclusion of sufficient number of patients difficult. In each participating 
hospital, the Medical Ethics Committee approved of the trial protocol. 
All patients who met the inclusion criteria but not the exclusion criteria were divided 
in two groups. Both groups were treated with intravenous prednisolone in a dose of 1 
mg/kg bodyweight on day one, to be diminished in equal steps during 7 days to 0 mg. 
In addition one group received aciclovir 10  mg/kg bodyweight intravenously three 
times daily for seven days; the other group received placebo. The hospital pharmacist 
performed randomization and aciclovir or placebo was given in identical bottles 
labeled " ISSHL Trial". Outpatient follow-up consisted of four consultations, 1 week, 
3, 6 and 12  months after discharge. 
After completion of the study participating patients and treating physicians and 
investigators were told whether aciclovir or placebo had been given. 
Audiometric and subjective parameters 
The audiometric parameters used for determining recovery were pure-tone audiometry 
in dB HL Extended Fletcher Index (EFI = average of thresholds at 0.5, 1 ,  2, and 4 
kHz) and speech audiometry. Pure-tone and speech audiometry were performed at 
inclusion and discharge, and repeated after 1 week, 3, 6 and 12  months. Our primary 
endpoint was hearing recovery after 12 months. 
Subjective parameters that the patients were asked to judge semiquantitavely were 
hearing recovery, tinnitus intensity, pressure sensation and vertigo. Hearing could 
be categorized as improved, equal or worsened. Tinnitus, pressure sensation and 
vertigo could be categorized as absent, mild, moderate or severe. These parameters 
were recorded before and after hospitalization and during outpatient follow-up. These 
subjective parameters were our secondary endpoints. 
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Data collection and statistical processing 
A Case Record Form (CRF) was used for data collecti on. For data processing a special 
spreadsheet program was designed to faci li tate data entry. Statisti cal processi ng was 
performed usi ng the statisti cal program SPSS 10. Data entry was controlled by 
frequency tables. 
Power analysi s: A 10  dB i mprovement i n  pri mary outcome was expected from the 
addi tion of aci clovir wi th an expected recovery i n  the placebo group of 35 dB. Alpha 
= 0.05 and beta = 0.2. We calculated the number of necessary patients wi th di fferent 
si gma's. Sigma (SD) = 10 then N = 32; sigma = 1 5  then N = 72; sigma = 20 then N 
= 126. 
Non-parametric  data was analyzed usi ng the Mann-Whitney test or Fisher's exact test. 
Parametric data were processed using t-tests for i ndependent samples, and � analysis. 
A 5% significance level was used. 
REsULTS 
Patient characteristics 
Between 1994 and 1 999, 9 1  Dutch and Flemish pati ents were i ncluded i n  the study 
(age 12-80 years; mean age: 46.8 ± 16.8 years; median: 47 years) . All patients were 
treated using the "intention-to treat-pri nciple". 
Forty-six patients received aciclovi r wi th predni solone (aci clovi r group) and forty­
five patients received placebo wi th prednisolone (placebo group) . Four patients were 
excluded after randomization due to the results of the di agnostic protocol, whi ch 
showed a known cause of thei r hearing loss (2 otosclerosis, 1 vesti bular schwannoma, 
and 1 bleedi ng cerebral peduncle) . 16 patients were excluded because of admi nistrati ve 
problems (CRF not correctly documented) . One patient refused further parti ci pati on 
after randomization. The remai ni ng patient group consisted of 70 patients; thei r 
characteristi cs are shown i n  Table 1 .  
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Table 1. Patient characteristics 
Placebo Aciclovir p-value Total patients 
(N = 33) (N = 37) (N = 70) 
Gender (2) 23 M, 10 F 23 M, 14 F 0.61 6  
Age (mean ± SO) ( I )  44.7 ± 17.6 45.9 ± 1 5.9 0.757 
Hearing loss in dB EFI at admission in 2 1 .2 ±20.7 dB HL 29.5 ± 33.2 dB HL 0.222 
unaffected ear (mean ± SO) ( I )  
Hearing loss i n  dB EFI a t  admission in 83.6 ± 28.0 dB HL 62.9 ± 2 1 .6 dB HL 0.002 
affected ear (mean ± SO) ( I )  
Virus infection i n  preceding momh {2) Neg = 25 Neg = 27 1 .000 Neg = 5 1 
pos = 8 Pos = 9 Pos = 1 5  
unknown = I 
Prev Herpes labialis (2) Neg = 26 Neg = 29 1 .000 Neg = 55 
Pos = 7 Pos = 7 Pos = 14 
Unknown = I 
Delay in days (mean ± SO) {I)  4.2 ± 3.4 4.4 ± 3.9 0.844 
(I): T-ttst; chi squar� (2-tail�d) 
(2): Crosstabs; Fish�r 's o:act t�st 
Of the 70 patients 4 patients had missing audiograms at 1 2  months, but we were able 
to extrapolate their hearing loss and could therefore still use their data for analysis. 
Extrapolation was possible because their hearing loss had been stable for the last 2 
outpatient follow-up consultations. Age and gender were equally divided between 
both groups. 
The mean hearing loss at admission in the aciclovir group was 62.9 dB HL, while 
in the placebo group the mean hearing loss was 83.6 dB HL. This was statistically 
significant (p = 0.002). 
The occurrence of previous infections was equally distributed between aciclovir- and 
placebo-treated patients (See Table 1 ) .  Time from onset to presentation was limited to 
14  days by our study protocol, even though one patient was included in our protocol 
after 1 6  days. This only became apparent after recalculation. This was not considered 
of having a significant influence on the end result of the trial and the patient was not 
excluded from analysis. Average delay for the whole group was four days (See Fig. 1 ) .  
There was no difference between the aciclovir and placebo groups. Median hearing 
loss for the whole group occurred in 2 hours and 23 minutes (range 1 minute to 
23:40 hours) . Almost 50% of the patients lost their hearing within one minute. This 
includes patients who first noticed their hearing loss on awakening (See Fig. 2). No 
seasonal influence could be established on occurrence of hearing loss in our patient 
group. 
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Figure 1. Patienr Delay 
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Figure 2. Onset of Hearing Loss 
Side effects 
All patients were able to tolerate both aciclovir/steroid and placebo/steroid schedule 
with only limited mild side effects. Mild side effects were transient and included 
slightly raised blood glucose, mild headache, palpitations and mild nausea. These side 
effects were interpreted to be the result of steroid therapy. No specific aciclovir side 




An intensive effort was made to demonstrate the presence of systemic viral infection. 
Although none of the patients had clinical symptoms of viral infection, in 8/70 
patient's serological signs of viral infection were present. 
A raised IgM antibody titer against varicella zoster virus was found in one patient and 
a dubious IgM reaction against mumps virus existed in another patient. 
Seroconversion against rubella occurred twice and a sign of an active non-primary 
Epstein-Bar virus infection was also demonstrated once. 
Herpes simplex type 1 was cultured from the nasopharynx in two patients and 
parainfluenza type 3 was cultured in one patient. None of these last three patients had 
a concomitant rise in antibody titer. 
Subjective data 
Subjective parameters noted were hearing recovery, pressure sensation, vertigo and 
tinnitus. Subjective hearing recovery closely followed audiogram parameters (figure 
not shown) .  Pressure sensation had a good prognosis, decreasing from 35. 1 %  to 1 5 .6% 
after 12 months in the aciclovir group and from 45.5% to 1 0.3% in the placebo group 
(See Fig. 3a). In 12  months time, vertigo decreased from 32.4% to 12.5% and from 
36.4% to 10.7% for aciclovir and placebo groups respectively (See Fig. 3b) . Tinnitus, 
however, showed a poor prognosis. At inclusion 86.5% of patients in the aciclovir 
group and 72.7% of patients in the placebo group suffered from tinnitus. After 12 
months this had decreased to 46.9% for the aciclovir group and to 55 .2% for the 
placebo group (See Fig. 3c). There was no statistical difference between the aciclovir 
and placebo groups in initial presentation or recovery (p > 0.05) for these subjective 
parameters. 
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Figure 3a. Subjective parameters: Pressure sensation 
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Figure 3b. Subjective parameters: Vertigo 
Tinnitus 




Pure-tone audiometry in Extended Fletcher Index (EFI) was used to quantify hearing 
levels. At admission hearing loss for the whole group was 72.7 dB EFL At 12  months 
endpoint hearing levels had improved to 45.5 dB EFL 
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The recovery 1 year after admission vs. initial hearing loss for the aciclovir and placebo 
groups is shown in a scatter plot (See fig. 4). The line drawn is a least squares fit 
with a quadratic curve. The average vertical distance to the curve for the aciclovir 
group is -3. 1  dB (SO 20.5 dB) and for the placebo group + 3.5 dB (SO 24.4 dB) . 
The placebo group shows a greater recovery after one year than the aciclovir group. 
However, the difference of 6.6 dB is statistically not significant. Figure 4 can therefore 
also be interpreted as the result for whole group of patients. There was no difference in 
recovery between aciclovir and placebo groups. Despite double blind randomization, 
more cases of profound hearing loss were allocated to the placebo group than to the 
aciclovir group. This however did not influence hearing recovery, as is shown in figure 
4. An analysis comparing hearing recovery for patients with hearing loss less than 100 
dB HL with patients with hearing loss larger than 1 00 dB HL showed no difference 
between the groups (Mann-Whitney Test, p > 0.05), thereby confirming the results 
in figure 4. Using the fitted line in figure 4 we calculated the hearing recovery for the 
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different initial hearing losses. The results are given in Table 2. 
Pure-tone audiogram shape was difficult to categorize in our patients. We were not 
able to establish a relationship between hearing recovery prognosis and pure-tone 
audiogram shape. 
Table 2. Calculated hearing recovery after I year 
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ISSHL is often regarded as an otological emergency. It is assumed that when treatment 
is initiated in the very early phase of the hearing loss, hearing recovery prognosis might 
be better. To verify this assumption, additional analysis was performed. We divided 
our patients into two subgroups: one in which treatment had begun within 24 hours 
after occurrence ofhearing loss (N=19) ,  and the remaining patients (N=5 1 ) .  Hearing 
recovery prognosis turned out to be comparable in both subgroups (p > 0.05). 
On average, a maximum speech discrimination score of 49% was achieved by patients 
when presenting with hearing loss. After 1 week of treatment, speech discrimination 
had improved to 59%, reaching 74% after six months. After 12 months speech 
discrimination score had reached 75%. Application of aciclovir had no effect on 
speech discrimination scores. 
Figure 5 is a histogram that shows the distribution of the vertical distance of all the 
points to the curve drawn in Figure 4. 
The distribution for the placebo group (not shown) is the difference between the 
total group and the aciclovir group. The standard deviation for the total group (the 
"width" of the histogram) is 22.4 dB. (This value can also be calculated from the 
already known SD's for the acyclovir and placebo groups) Clinically important is the 
speed of recovery. Figure 6 shows the time it takes patients to reach 80% of their total 
recovery. The data in this curve contain only those patients who have shown recovery, 
i.e. their initial hearing loss was greater than their hearing loss after 1 year (n=33 for 
the aciclovir group and n= 27 for the placebo group) . 
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About half of the patients reach their 80% recovery after only 2 weeks. The aciclovir 
group with a fast recovery is larger than the placebo group with a fast recovery. The 
probability that both groups have the same speed of recovery is 20% (Mann-Whitney­
Wilcoxon-test) . This p-value (p=0.2) is so large that the difference between both 
distributions is not significant. On average a patient will reach 80% recovery in about 
seven weeks. 
DISCUSSION 
Etiology and treatment of Idiopathic Sudden Sensorineural Hearing Loss (ISSHL) 
are still open to debate, even after 60 years of research 15• It affects patients to the 
core of their existence and has serious repercussions on their social and professional 
functioning. Most ISSHL patients experience some hearing recovery after treatment 
with corticosteroids. The majority does so in the first two weeks after treatment. 
In our patient group we calculated expected hearing recovery for several different 
initial hearing losses (see Table 2). With a few exceptions there appears to be a limit 
of recovery for the cochlea of around 35 dB. In this study addition of aciclovir to 
corticosteroid therapy did not improve hearing recovery as compared to corticosteroid 
therapy alone. 
Secondary endpoints (subjective parameters) such as vertigo and pressure sensation, 
which affect about one third of patients, have a good prognosis and also show recovery. 
A large proportion of patients suffer from tinnitus. This has a poor prognosis and this 
very often remains a lasting effect of ISSHL. Addition of aciclovir unfortunately did 
not improve any these subjective complaints. 
In ISSHL, the delicacy of the structures involved makes elucidation of and interference 
with its pathophysiology difficult. In our experience, no truly successful treatment 
regimen can be offered to ISSHL patients, despite the mild beneficiary effect of 
corticosteroids. Although we have not been able to ascertain the therapeutic value from 
the application of aciclovir in ISSHL in this study, some methodological limitations 
are apparent which might explain our results in part. 
In our study, a multicenter approach covering the entire Dutch language region (2 1 . 5  
million inhabitants) was necessary to include our 9 1  patients. This group might still 
have been too small to achieve statistical significance. Almost every study concerning 
ISSHL suffers from this limitation, because of the low incidence of the condition, 
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especially when in- and exclusion criteria are strictly applied. Our definition of 
ISSHL was somewhat stricter than the definition used in Wilson or Moskowitz's 
study IO; I I , but was similar enough to allow comparison between our patient group 
and patient groups reported in these and other studies. Secondly, to prove efficacy 
of any therapeutic modality in ISSHL, it has to perform significantly better than the 
high spontaneous recovery rate, reported to be between 40-65%. Thirdly, the range 
in hearing recovery was larger than we expected (SD) and therefore our sample size 
might still have been too small. 
Fourthly, despite double-blind randomization, we failed to control for severity of 
initial hearing loss in this study. There was a statistical significant difference between 
aciclovir and prednisolone groups in severity of initial hearing loss of affected ear at 
admission. The hospital pharmacist randomized the patients in blocks of four. The 
only information the hospital pharmacist had prior to randomization was name, age 
and weight of patient. After analysis of the randomization procedure no explanation 
could be given as to the reason for this difference between both groups. The other 
relevant criteria were evenly distributed between the acyclovir and placebo groups. 
The prognostic factors in ISSHL mentioned in the literature include vertigo or 
vestibular involvement, audiogram shape and severity of initial hearing loss. These 
factors can be used as an indication of the severity of the damage to the structures in 
the inner ear. In general, patients with mild to moderate hearing loss without vertigo, 
who ate seen quickly after initial presentation of the hearing loss, have a better chance 
of recovery 16• 
Prognosis of hearing loss with or without vestibular involvement was comparable in 
our patients. Vestibular involvement has been suggested to indicate more extensive 
damage to the labyrinth, with a relatively unfavorable prognosis as a result17• In our 
study vertigo had a relative good prognosis and did not influence recovery, consequently 
this could not be confirmed as an indicator of poor recovery. 
Secondly, audiogram shape as a prognostic factor is often used to characterize severity 
and location of damage to the cochlea. Pure tone audiogram shape was difficult to 
categorize in our patients, therefore we could not correlate audiogram shape with 
recovery. 
Thirdly, severity of initial hearing loss is used as an indication of more severe damage 
to the cochlea. This theoretically lowers the potential recovery. In our study absolute 
recovery in dB depended only weakly on initial hearing loss (see fig. 4 and table 2) . 
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We hypothesized that the cochlea has a maximum potential recovery of around 35-
45 dB. Depending on the severity of initial hearing loss, this would mean either full 
recovery, for losses up to 45 dB; limited recovery, for losses 45-80 dB; or no (functional) 
recovery for losses > 90-1 00 dB. 
The failure to demonstrate the effectiveness of aciclovir for patients with ISSHL has 
forced us to readjust our theory regarding the etiology of ISSHL. The three main 
hypotheses concerning the etiology of ISSHL mentioned in the literature are a 
circulatory disturbance, a membrane rupture or a viral cause. Despite an extensive 
diagnostic protocol we could not identify a single etiologic cause. As ISSHL affects all 
age groups, is evenly distributed between sexes and no coagulopathy or autoimmune 
disorder could be demonstrated, we consider a circulatory disorder highly unlikely. 
The spontaneous occurrence of ISSHL without a history of (baro)trauma, even 
while asleep makes a membrane rupture doubtful. Histopathology suggests a viral 
etiology and the significant yet mild beneficiary effect of steroids at least suggests an 
inflammatory component. Although we could not prove a viral infection as a cause 
of ISSHL with serology techniques, this doesn't mean that there was no infection, 
be it a primary infection or reactivation. Testing perilymph or endolymph samples 
in patients with ISSHL for viral DNA using PCR (polymerase chain reaction) could 
prove this. This is ethically not feasible, as there would be a significant possibility of 
permanent hearing loss. 
In conclusion we can say that circumstantial evidence still points to a viral infection, 
probably from a neurotropic virus such as herpes simplex as a cause for ISSHL. 
Although the combination of aciclovir combined with steroids is the preferred 
treatment for known herpetic infections, there seems to be no place for aciclovir in the 
treatment ofiSSHL. Considering that the anti-inflammatory effect of corticosteroids 
is thought to play an important part in the recovery, a more powerful suppression 
of the immune system might enlarge or quicken the recovery in ISSHL. This could 
be achieved using high-dose glucocorticoid therapy (pulse therapy) . Pulse therapy 
combines a large anti-inflammatory effect with limited side effects18• Pulse therapy 
has shown positive results for diseases as diverse as rheumatoid arthritis, optic neuritis, 
multiple sclerosis, and pemphigus vulgaris. 18-22• 
Proof of effectiveness of new therapeutic initiatives must be studied in large trials 
for proper evaluation. Only then can evidence based medicine contribute to a better 
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Chapter 5 
INTRODUCTION 
High -dose glucocorticoid pulse therapyaims atperiodicallystrongimm unosuppression 2• 
As adjuvant in chronic inflammatory disorders, pulse therapy may reduce the 
daily maintenance dose of glucocorticoids thus limiting the hazards of continuous 
long-term steroid intake. The largest experience with glucocorticoid pulse therapy 
in dermatology is obtained in patients with pemphigus vulgaris, a life-threatening 
autoimmune skin disease in which autoantibodies cause loss of epidermal cohesion, 
and therefore blistering. Pasricha et al. described both a steroid-sparing effect and 
long-term remission of up to 9 years, using pulse therapy 2• More recently use of 
glucocorticoid pulse therapy has been advocated in Idiopathic Sudden Sensorineural 
Hearing Loss (ISSHL), in which patients experience a sudden hearing loss of unknown 
origin. It is believed that a subclinical viral labyrinthitis triggers an immune response 
in these patients which damages the sensory epithelium of the inner ear 3• 4 • 
In pulse therapy high-dose glucocorticoids are administered every month on three 
consecutive days. Type of glucocorticoid and dose per pulse is not standardised but 
usually 500-1 000 mg methylprednisone per pulse or 1 00-200 mg dexamethasone 
per pulse is administered 5• Dexamethasone has a number of advantages over other 
glucocorticoids: negligible sodium-retaining properties, a stronger intrinsic activity, 
and no presystemic metabolism. Moreover dexamethasone is less likely to cause serious 
cardiac dysrhythmias than other glucocorticoids 6• 
Pulse therapy is mostly given intravenously rather than orally, without evidence to 
support the necessity of the intravenous route. Oral pulse therapy is preferable, since 
it avoids a vena-puncture, decreases costs, and is more convenient for the patient. 
To develop a suitable dosage for oral dexamethasone pulse therapy, bioavailability 
of high-dose dexamethasone had to be determined. A recent study reports the 
bioavailability of oral high-dose dexamethasone (1 00 mg capsules) of 63.4%. 
Dexamethasone 300 mg per os is therefore equivalent to approximately 200 mg 
dexamethasone iv, the standard iv. pulsed dose 1 •  
In  this study, the pharmacokinetics of a new dexamethasone formulation was studied, 
namely 50 mg tablets for oral use in pulse doses of 300 mg. If the results of this study 
is satisfactory, these tablets will be used in two prospective multicenter double-blind 
randomised clinical trials, in which the effect of oral high-dose dexamethasone pulse 
therapy will be evaluated in patients with pemphigus vulgaris or ISSHL 
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MATERIAL AND METHODS 
Subjects 
Four patients with pemphigus vulgaris were enrolled in this study, three males with 
an average age of 46 years (range 33-57) , and a 54 year old female. One of the male 
patients suffered from diabetes. 
Patients were admitted for their monthly pulse therapy. Prior to pulse therapy safety 
parameters in blood (full blood count, electrolytes, liver and kidney functions and 
glucose) and urine (sediment, reduction) were measured. On two consecutive days 
patients were given 200 mg dexamethasone intravenously, and 300 mg dexamethasone 
orally. During pulse therapy heart rate and blood pressure were monitored. Clinical 
effects were not studied. 
Drug administration 
For intravenous administration dexamethasone phosphate was used. Tablets containing 
50 mg dexamethasone were produced in our hospital pharmacy, since high-dose 
dexamethasone tablets are not available in the Netherlands. The dexamethasone (Eur. 
Pharm) was hydrophylised with methylcellulose 1 5  MPA-s (Eur. Pharm) . The tablets 
were prepared by direct compression using cellulose microcrystalline (Eur. Pharm, 
Avicel pH 101 ) ,  and magnesium stearate (Eur. Pharm). 
In vitro control of content uniformity of 50 mg dexamethasone proved more reliable 
than a 1 00 mg dosage, as dexamethasone is practically insoluble in water. For the 
planned clinical trials a charge of 30.000 units was produced, which is in our setting 
easier to produce in tablets than in capsules. Furthermore correction of taste is easier 
in tablets. 
Tablets were white, diameter 7 mm, thickness 3.5 mm, and no inscription. Mean tablet 
weight (n= 12) was 20 1 .7 mg with coefficient of variation of 1 .04% (requirement <3% 
n= 1 0). Tablets satisfied the tests for tablets according to BP 1998. The dissolution test 
showed a dissolution of 38.3 % of dexamethasone after 45 minutes, uniformity of 
content was 103.3 % (requirement 85-1 1 5%) .  Tests on identity, uniformity of mass, 
uniformity of content, disintegration and purity were all conform requirements. 
Sample collection 
Blood samples were drawn in non-heparinised tubes, after intravenous administration 
at times 0; 1 ;  2; 3; 4; 6 and 24 hours and after oral administration at times 0; 1 ;  2.5;  3; 
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3.5; 4; 8 and 24 hours. Serum was obtained after centrifugation {at 1 500 g, at ambient 
temperature then stored at -20°C until analysis. 
Analysis 
Serum samples were analysed by a validated suitable selective high performance liquid 
chromatography procedure. 
Chromatographic separation was performed using a Chromsphere 5C1 8  analytical 
column (250 x 4.6 mm I.D.) after a guard column (Chrompack R.P. 10  x 2 . 1  mm). 
A high pressure pump (spectroflow 300 solvent delivery system) and an autosampler 
{Merck-Hitachi, model AS-2000) were used. For detection, we used a diode array-UV 
detector (Gynkotek) at 244 nm with computer software to achieve data handling and 
peak integration. The mobile phase was a mixture of phosphate buffer (0.067 M; pH 
6.9), tetrahydrofurane and ultra pure water { 1  :2:5 v/v/v) at a flow rate of 1 .25 ml/min. 
During analysis the mobile phase was stirred. The samples were purified by a liquid­
liquid extraction. Betamethasone ( 1  0 mg/L) was used as internal standard. 
To one m! of serum, 100 JlL of internal standard solution and 6 ml of diethylether 
were added. After shaking for 1 5  minutes and centrifugation at 1 500 g for 5 minutes, 
the water layer was frozen at -40°C. 
The organic layer was carefully decanted into clean centrifuge tubes and was evaporated 
to dryness at 35°C under nitrogen. The residue was dissolved in 100JlL of mobile 
phase and 50 JlL of aliquot was injected into the chromatograph. From recorded 
peak heights, the ratios of drug to internal standard were calculated. The analytical 
procedure has been validated 7• Linearity {range 20-750 Jlg/L), precision and accuracy 
have been proven. In testing the method it appeared to give a linear response to at 
least 3400 Jlg/L. Samples with concentrations above 3400 Jlg/L were re-analysed after 
a validated dilution step. The day to day coefficients of variation were 13.6% ( C=20.0 
Jlg/L) and 2.0% ( C= 99.9% Jlg/L) respectively ( n= 1 5) .  The day to day inaccuracy 
varied between 97.5 to 102. 1 o/o. The lower limit of quantitation was 20 Jlg/L. In the 
previous study using dexamethasone capsules ( 1  OOmg) the same analytical procedure 
and extraction were used 1 •  
For pharmacokinetic analysis the computer program MW/PHARM {Mediware, 
Groningen, the Netherlands) was used. This program calculates a set of pharmacokinetic 
parameters that best fits the measured serum concentrations in time. In the curve 
fitting module Kinfit the optimal compartment model is fitted. In the module Kinbes 
bioavailability of oral administered dexamethasone was calculated using AUC {area 
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under the serum concentration-time curve) ratios with trapezoidal rule. In Kinbes 
bioavailability is calculated using the following equation 8: 
F = (AUC.,1 x dose ,) I (AUCi.u x dose.,) x I 00% 
Kinbes corrects the outcome of this formula for differences in elimination constants 
that are determined for oral and intravenous administration. AUCo..t and AUCi.v. 
is the area under the serum concentration time curve of the oral and intravenous 
administration respectively. For both oral and intravenous administrations the time 
course of dexamethasone serum concentrations was characterised by peak concentration 
(C ) ,  time of reaching peak concentration (t ), area under the curve (AUC) and mu mu 
elimination half-life (t1 12) .  These parameters were calculated in the module Kinbes. 
REsULTS 
Bias of measured concentration of the quality control samples with respect to the true 
concentration was calculated. For the lower quality control sample (335 }lg/L) a mean 
bias of -1 .69 o/o was calculated. None of the outcomes exceeded 20%.  For the high 
quality control sample (3464 }lg/L) a mean bias of 4.82 % was calculated with also 
none of the results exceeding 20 o/o. All runs were accepted. 
Figure 1 shows the mean serum concentration-time curve for both oral and intravenous 
administration of dexamethasone. The serum concentration-time curves corresponding 
to these administrations were best described by a tri-exponential equation. 
Table 1 summarises all pharmacokinetic parameters. Mean bioavailability of the tablets 
was 55.8 o/o (range 43-65%). Mean peak concentration after 200 mg dexamethasone 
iv. was 5040 }lg/L, after 300 mg dexamethasone per os 2580 }lg/L. Mean time to peak 
concentration is 2.25 hours for oral administration. 
Little variation in peak concentration was found among the four patients. Mean peak 
concentration after oral administration is 5 1 .2 % of the mean peak concentration 
after intravenous administration. 
In patient D dexamethasone was quantifiable 2 1  hours after intravenous administration 
(83 }lg/L) . Dexamethasone was also quantifiable 24 hours after oral administration ( 10 1  
}lg/L) . These results were confirmed by reanalysing the corresponding samples using 
LC-MS with APCI interface. Hydrocortisone-3D was used as an internal standard 
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replacing betamethasone (a stereoisomer of dexamethasone). In the MS-spectrum 
an obvious peak corresponding to dexamethasone was seen, thereby confirming the 
presence of dexamethasone in these samples. 
Side-effects in the four patients were limited to facial flushing, and sleeping disturbances 
the first night after administration. 
Table 1: Pharmacokinetic parameters of dexamethasone after intravenous and oral administration of 200 and 300 mg 
respectively 
Therapy Patient A Patient B Patient C Patient D Mean so 
• 200 mg iv. 
- AUC(mg/1/h) 17.36 9.52 17.45 21 .76 1 6.52 5.10 
- c  .... (mgll) 4.44 4.72 5.99 5.00 5.04 0.67 
- t,, (h) 2.1 5 1 .39 2.92 3.78 2.56 1 .03 
• 300 mg p.o. 
- AUC (mg/1/h) 1 5.88 6.64 14.67 24.74 1 5.48 7.41 
- C,u, (mg/1) 2.79 1 .84 2.34 3.35 2.58 0.64 
- t..,. (h) 3.5 3.5 1 .0 1 .0 2.25 1 .44 
- t,, (h) 2.84 1 .52 3.05 4.39 2.95 1 . 17 
- F (%) 6 1  43 54 65 55.8 9.64 
DISCUSSION 
The mean bioavailability of high-dose dexamethasone tablets was 55 .8  % (range 43-
65%). The dose of 358 mg dexamethasone per os is therefore equivalent to 200 mg 
dexamethasone iv . .  
Bioavailability does not differ significantly when 50 mg tablets (58.8%) or 100 mg 
capsules (63,4%) are used for high-dose dexamethasone pulse therapy (6) . When 
tablets of 50mg were used mean dexamethasone peak concentration (Cm.) was 52% 
(range 37-66%), which is lower than after administration of the capsules (mean 
72.3%; range: 67-79%) (6) . 
Since it is unknown whether the effects of pulse therapy are due to Cmax or AUC and 
the bioavailability (AUC) of the tablets was comparable to capsules we concluded 
that 300 mg oral dexamethasone in 50 mg tablets can be used as oral pulse therapy. 
Therapeutic effects of the oral pulse therapy will be studied separately 9• 
The elimination half-life for one patient was large compared to the other patients, 
possibly due to interindividual variation in pharmacokinetics. This prolonged half 
life would not cause any risk for the patient in terms of side effects, since the serum 
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concentration was extremely low compared to the peak concentration. Besides pulse 
therapy is only administered on 3 consecutive days, once a month. 
Oral pulses, instead of iv, reduce patient inconvenience, increases cost-effectiveness, 
and are more acceptable in placebo controlled trials. Tablets are preferable instead of 
capsules, for better in vitro control of content uniformity and better taste correction. 
Intake of tablets is more convenient than of capsules for the patient. 
The new dexamethasone tablets have reliable pharmacological and technical 
characteristics, and appear to be safe. They can be safely used for high-dose pulse 
therapy, and are suitable for use in the planned clinical trials, in which the therapeutic 
effect of oral high-dose dexamethasone pulse therapy is evaluated. 
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INTRODUCTION 
Sudden deafness is characterized by sensorineural hearing loss of 30 dB HL or 
more over at least 3 sequential 1-octave frequency steps in the standard pure tone 
audiogram, which develops over a period ranging from a few hours to three days in 
otherwise normally hearing, healthy individuals. It affects between 5 and 20 persons 
per 1 00,000 annually. The hearing loss is usually unilateral and frequently associated 
with vestibular disturbances, tinnitus and a pressure sensation in the ear 1• Most studies 
report spontaneous partial recovery in 45% to 65% of patients, although hearing will 
recover to functional levels in only a small number of patients. 
Although sudden deafness is a well-recognized condition, no standard definition 
or treatment protocol has been accepted. In addition, despite extensive evaluation, 
an etiological factor can only be found in 1 0-15% of patients 2• Viral infections 3 ,  
disturbances i n  the microcirculation 4 and cochlear membrane ruptures 5 are all entities 
that have been hypothesized as causes of idiopathic sudden sensorineural hearing loss 
(ISSHL). 
The two main theories concerning the aetiology of ISSHL are disturbances in the 
microcirculation and a viral infection of the inner ear. 
A disturbance in the inner ear microcirculation is unlikely because sudden deafness 
occurs in individuals of all ages, is evenly distributed among sexes and no coagulopathy 
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can be found in patients with ISSHL. Furthermore, experimentally induced hearing 
loss of vascular origin is irreversible and vaso-active therapy has yet to show a positive 
effect on hearing improvement. 
Viral infections such as measles, mumps, rubella and herpes can cause sudden 
hearing loss. Moreover, the histories of around 30% of sudden deafness cases include 
infections of the upper respiratory tract 2• Magnetic resonance imaging studies of 
the inner ear have shown labyrinth enhancement in patients with sudden deafness 6• 
Post-mortem cochlear histopathological changes seen in patients with ISSHL closely 
resemble changes seen after viral labyrinthitis 7• Liao et al. 8 suggest a virally-mediated 
immune response causing the cochlear damage, and thus the hearing loss, as a possible 
pathophysiology for ISSHL. The immune response can provoke the degeneration of 
the organ of Corti, stria vascularis and spiral ganglion 9• 
The only form of treatment that has shown some effect in improving hearing after 
ISSHL is the administration of corticosteroids as quickly as possible after the onset 
of hearing loss 10• The mechanism of steroid action in the inner ear remains open to 
speculation; they reduce the cytotoxic immune response, increase the microvascular 
blood flow in the cochlea and decrease the onset of endolymphatic hydrops 1 1 •  
Considering that the anti-inflammatory effect of corticosteroids is thought t o  play 
an important part in the recovery from ISSHL, a more powerful suppression of the 
immune system might enhance or quicken recovery. This could be achieved with 
high-dose corticosteroid therapy (pulse therapy) . Pulse therapy combines a large anti­
inflammatory effect with limited side effects 1 2• Pulse therapy is the discontinuous 
administration of corticosteroids in very high doses. The pulse doses are not 
standardized but usually range between 10 and 20 mg/kg for methylprednisone and 
between 2 and 5 mg/kg for dexamethasone. A dose of 500 mg methylprednisone or 
100 mg dexamethasone roughly equals 625 mg prednisone 1 2• 13• 
The present study was based on an earlier study which evaluated whether the addition 
of acyclovir to prednisone leads to better hearing recover than prednisone alone 1 4 •  
In this study we evaluate whether pulse therapy or high dose dexamethasone leads 




MATERIALS AND METHODS 
Inclusion and exclusion criteria 
Patients participating in the trial met the following criteria: 1 )  perceptive hearing 
loss of unknown aetiology; 2) hearing loss of at least 30 dB hearing level (HL) for 3 
subsequent 1 -octave steps in the standard pure tone audiogram (PTA); 3) Hearing 
loss occurred within twenty-four hours; 4) blank otologic history of the affected ear. 
Patients were excluded if the hearing loss had occurred more than fourteen days before 
evaluation, had fluctuating hearing loss or if they had contraindication to the use of 
high-dose steroids. (Table 1 :  Contraindications for Pulse Therapy) . 
Table 1. Contraindications for the use of Pulse Therapy 
A. serious infections: herpes simplex oculi, active tuberculosis 
B. hypertension (diastolic > 1 10 mg Hg, systolic > 180 mmHg; treated or untreated) 
C. manifest decompensatio cordis 
D. cardiac arrhythmias, with the exception of atrial fibrillation 
E. low serum potassium (below patient's own hospital's reference value) 
F. severe osteoporosis 
G. Cushing syndrome 
H .  badly regulated insulin-dependent diabetes mellitus 
I. ulcer 
J. pregnancy 
K. oral anticoagulants (cumarin derivatives) 
L. use of corticosteroids 
Diagnostic protocol 
In order to exclude known-causes of hearing loss, we submitted patients to a 
diagnostic protocol. This included a complete history and physical examination, 
audiological and vestibular tests, magnetic resonance imaging of the temporal bone 
and cerebellopontine angle, and laboratory work-up. Laboratory investigations were 
aimed at excluding the presence of an infectious, inflammatory, autoimmune process 
or coagulopathy. An extensive serological evaluation for HSV, varicella-zoster virus, 
cytomegalovirus, Epstein-Barr virus, mumps, measles, influenza, parainfluenza, 
rubella, Borrelia, chlamydia and syphilis was performed on paired blood samples 
and with a nasopharyngeal swab or aspirate. Consulting specialists in opthalmology 
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and internal medicine were asked to exclude Cogan's syndrome and systemic disease, 
respectively. After diagnostic samples were taken, a provisional diagnosis of ISSHL 
was made and treatment was initiated. In cases where a cause of sudden hearing loss 
was identified later, patients were excluded from the study. 
Informed consent 
Before participation, patients were given oral and written information about the study. 
Before participating in the study, patients were required to sign a written informed 
consent form, designed in line with the European Good Clinical Practice regulations. 
Patients had to be 1 8  or older to be eligible for participation. 
Study design 
The study was designed as a prospective, randomized, double-blind clinical trial. A 
multicentre approach was necessary because the low incidence of ISSHL makes the 
inclusion of sufficient numbers of patients difficult. Patients were recruited from 
April 2000 to October 2004. Each participating hospital's respective Medical Ethics 
Committee approved the trial protocol. 
Medication 
Patients were randomly allocated to pulse therapy or control treatment. Pulse therapy 
consisted of 300 mg dexamethasone for three consecutive days followed by four days 
of placebo. Control treatment consisted of 70 mg prednisone per day tapered in steps 
of 10  mg per day to 0 mg. The treatment lasted seven days for both groups. Each 
patient took 7 tablets for the first three days, then 4 tablets on day four and 3 tablets 
on the last three days. Outpatient follow-up consisted of 4 consultations at 1 week, 6 
weeks, 6 months and 12  months after discharge. 
The trial medication was pre-packaged and supplied in identical sterile packaging 
with a label specifying the days of the regimen. 
All trial medication was prepared at the University Medical Centre Groningen 
dispensary to ensure stable pharmacodynamics and pharmacokinetics. The hospital 
dispensary performed randomization. 
The medication was randomized per block and was given a serial number. The order 
of the serial number determined the order of dispensing. Once an ISSHL patient 
had been included in the study, the pre-packaged trial medication was delivered to 
the patient's physician. In order to ensure that the medication was given as quickly as 
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possible, a supply of ten pre-packaged medication packages was stored at each of the 
participating academic hospitals. 
Audiometric and subjective parameters 
The primary endpoint was recovery of hearing measured after 12  months. Recovery of 
hearing was defined as the difference between hearing loss on presentation and after 
12  months. Hearing loss was measured with pure tone audiogram (PTA) and speech 
audiogram. The Extended Fletcher Index (EFI) was used to calculate hearing loss. EFI 
is mean hearing loss at (500+ 1000+2000+4000) Hz. PTA and speech audiometry 
were performed at inclusion and discharge and were repeated after 1 week, 6 weeks, 
6 months and 1 2  months. We believe that after 12 months no further recovery can 
be expected. 
Subjective parameters that the patients were asked to judge semi-quantitatively were 
hearing recovery, tinnitus, pressure sensation and vertigo. Hearing could be categorized 
as improved, equal or worsened. Tinnitus, pressure sensation and vertigo could be 
categorized as absent, mild, moderate or severe. These parameters were recorded 
at inclusion and discharge and were repeated during outpatient follow-up. These 
subjective parameters were our secondary endpoints. 
Data collection and statistical analysis 
A case record form was used for data collection. For data processing, a special 
spreadsheet programme was designed to facilitate data entry. Statistical processing 
was performed using the statistical programme SPSS 12 .  Data entry was controlled by 
frequency tables. 
A 10 dB improvement in primary outcome was expected from pulse therapy with an 
expected recovery in the control group of 45 dB (alpha 0.05, Beta = 0.2). The N's were 
forced to be equal. 
Two-sample T-test power analysis calculated that 5 1  patients per group were required. 
The total number of patients needed therefore was 1 02.  
All quantitative variables and the changes between groups were calculated with the 
student's T-test. Qualitative variables were assessed with the X2 -test. 
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Table 2: Trial Profile 















































Between 2000 and 2004, 9 1  Dutch and Flemish patients were included in the study. 
The hospital pharmacy randomly allocated 47 patients to the prednisone group and 
44 to the dexamethasone group. See table 2 for the trial profile. After completing 
the diagnostic protocol, 5 patients were excluded owing to known causes of their 
hearing loss being identified (prednisone group: 1 positive IgM for Borrelia, 1 active 
herpes zoster oticus, 1 paraneoplastic hearing loss and 1 patient who had psychiatric 
hearing loss; 1 patient in the dexamethasone group had bleeding in the cochlea, as 
identified on the MRI-scan) . Five patients were excluded because of incomplete data. 
The remaining patient group consisted of 8 1  patients and their characteristics are 
shown in table 3.  All these patients were included for treatment. 
Table 3. Patient characteristics 
Prednisone Dexamethasone Total patients 
( N  = 40) (N = 4 1 )  (N = 81 )  
Sex 19  M, 21  F 25 M, 16 F 8 1  
Age (y; mean ± SD) 49 ± 16 46 ± 1 5  8 1  
Hearing loss at admission in unaffected ear 1 9  ± 20 1 6  ± 1 6  8 1  
( dB HL EFI; mean ± SD 
Hearing loss at admission in affected ear 75 ± 28 71 ± 27 8 1  
(dB HL EFI; mean ± SD) 
Delay in days 3 ± 3  4 ± 4  81  
Virus infection in preceding month Negative 31 (38%) Negative 28 (34%) 81  
Positive 8 (10%) Positive 1 1  ( 1 4%) 
Unknown I ( 1  o/o) Unknown 2 (2%) 
Previous herpes labialis Negative 27 (33%) Negative 33 (41 o/o) 81  
Positive 1 2  (1 5%) Positive 6 (7%) 
Unknown I ( 1%) Unknown 2 (2%) 
Adverse effects 
All patients were able to tolerate the medication with only limited, mild side effects. 
These included mild headache, palpitations, euphoria and mild nausea. All patients 
showed transient increase in their blood workup {day 3) of blood glucose and white 
blood cell count. All values returned to normal and, more importantly, during the 
therapeutic stage of the trial there was no difference in reaction between prednisone 
and dexamethasone. 
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Serological evaluation 
An extensive effort was made to demonstrate the presence of an infectious, inflammatory 
or autoimmune process or coagulopathy. Two patients were excluded because of active 
infection; one patient had positive IgM for Borrelia and one patient had clinical 
herpes zoster oticus (varicella-zoster virus) with concomitant rise in antibody titer. 
Two patients had a raised IgM titer for influenza A, two had raised CMV IgM titers 
and one patient had a raised IgM for mycoplasma pneumoniae. Positive IgG titers 
were much more common, especially for EBV (4 1 patients) , Rubella (37 patients) , 
VZV ( 1 6  patients) and HSV ( 13  patients). Cultures from the nasopharynx were all 
negative. 
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Figure 1. Pacienr delay. Delay from onset of the hearing loss until presentation at the clinic. 
Patient characteristics 
14 
As shown in table 3, patient groups were comparable in age, gender, hearing loss in the 
affected ear and hearing loss in the unaffected ear. The occurrence of previous upper 
respiratory infections or previous herpes labialis was equally distributed between the 
prednisone and dexamethasone groups. Time from onset to presentation was limited 
to 14 days by our protocol. Figure 1 shows the distribution for the whole group. 
The average patient delay for the prednisone group was 3 days and 4 days for the 
dexamethasone group. The hearing loss usually developed rapidly, with almost 60% 
of patients losing their hearing in the first minute. This figure includes patients who 
first noticed their hearing loss on awakening. 
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The median time for patients to lose their hearing across the whole group was 2 hours, 
32 minutes (range: 1 minute to 22 hours, 30 minutes) (Figure 2) . No seasonal influence 










1 0  
o +-�-+�--�+-�����r-��-+�--+ 
0 500 1 000 
Time (minutes) 
Figure 2. Development of the hearing loss: onset in minutes. 
Subjective data 
1 500 
The subjective parameters noted were hearing recovery, pressure sensation, vertigo 
and tinnitus. Subjective hearing recovery closely followed audiogram changes (data 
not shown) . In 12 months, pressure sensation and vertigo had a good prognosis but 
tinnitus did poorly, only decreasing from 85% to 69% in dexamethasone-treated 
patients and from 95% to 58% in prednisone-treated patients. This remains one of the 
lasting and most burdensome side effects of ISSHL (Figure 3A) . Vertigo had a good 
prognosis, decreasing from 26% to 13% in the dexamethasone group and from 37% 
to 1 0% in the prednisone group (Figure 3B). Pressure sensation in the affected ear had 
the best prognosis in this study, decreasing from 46% to 9% in the dexamethasone 
group and from 54% to 1 6% in the prednisone group (Figure 3C). There was no 
statistically significant difference between the study groups in subjective parameters. 
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Figure 3a. Subjective parameters: Tinnitus. The percentage of patients suffering from tinnitus, for both patient groups. 
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Figure 3b. Subjective parameters: Vertigo. The percentage of patients suffering from vertigo, for both patient groups. 
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Figure 3c. Subjective parameters: Pressure sensation. The percentage of patients suffering from pressure sensation, for 




Pure tone audiometry using the Extended Fletcher Index (EFI) was used to calculate 
hearing loss and recovery. Maximum speech discrimination was defined as the 
maximum percentage of words that patients recognized at their optimal sound level. 
Of the 8 1  patients, 1 0 had missing audiograms at 12  months (5 in the prednisone 
group, 5 in the dexamethasone group). fu these audiograms could not be retrieved, 
the primary endpoint was calculated using the remaining 7 1  patients. Age, gender, 
hearing loss at inclusion and hearing loss in the unaffected ear were equally divided 
between these groups and the 'loss' of 10  patients did not influence mean audiometric 
or maximum speech discrimination. 
In a 12-month period, average hearing for the whole group improved from 72 dB HL 
to 39 dB HL and speech discrimination improved from 42o/o to 78o/o. If the study 
groups are considered separately, hearing improved from 71  dB HL (SD 27 dB) to 
36 dB HL (SD 28 dB) in the dexamethasone group and from 75 dB HL (SD 28 
dB) to 42 dB HL (SD 29 dB) in the prednisone group (p>0.05). Figure 4 shows the 
hearing loss in EFI for both groups as a function of time. It shows the median and the 
interquartile range for dexamethasone and prednisone. 
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Figure 4. Hearing loss as a function of tim�. for both patient groups. Thick lines indicate the m�dian, thin lin�s the 25'h 
and 75'h percentile. 
Hearing loss after a year as a function of initial hearing loss is shown in a scatter plot 
for the dexamethasone and prednisone groups in figure 5. There is no significant 
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statistical difference between the two groups (p>0.05) . Lines are added that show 
'no recovery' and 'normal hearing' , with normal hearing being defined as 20 dB EFI 
hearing loss or less. Figure 5 can therefore also be interpreted as the result for the 
whole group of patients. 
Further analysis was conducted to evaluate whether patients had regained symmetrical 
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Figure 5. Hearing loss at 12 months compared to hearing loss at admission, for all patients. The boundaries for patients 
showing no recovery, as well as for patients regaining normal hearing are indicated. 
In the dexamethasone group, 22/36 patients (61 o/o) regained symmetrical hearing 
and 1 9/35 patients (54%) in the prednisone group (p>0.05), thereby confirming 
the results in figure 5. Despite there being no difference, this does mean that 4 1 /7 1  
patients (57%) regained symmetrical hearing in both groups. Another way of looking 
at recovery is to define recovery as a more than 50% decrease in hearing loss at 1 2  
months when compared to initial hearing loss. Accordingly, i n  the dexamethasone 
group, 2 1 /36 patients (58%) attained a 50% decrease, while 14/2 1 patients (40%) 
recovered 50% of their hearing loss (p>0.05) in the prednisone group. 
An analysis comparing recovery in patients whose initial hearing was less than 1 00 dB 
HL with those whose hearing loss was greater than 1 00 dB showed no difference. 
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ISSHL is often regarded as an otological emergency. It is assumed that when treatment 
is initiated at a very early phase of the hearing loss, the prognosis for recovery might be 
better. To verify this assumption we divided our patients into two subgroups: patients 
for whom treatment had started within 24 hours after the occurrence of hearing loss 
(N = 24) and the remaining patients (N = 47) . Hearing recovery turned out to be 
comparable. The mean speech discrimination score at presentation was 4 1 %  for the 
whole group (39% for the dexamethasone group and 42% for the prednisone group) , 
after 12  months this had increased to 78% (dexamethasone and prednisone groups 
both reached 78%) . The percentage of patients reaching 1 00% speech discrimination 
scores is shown in figure 6. The dexamethasone group did slightly better than 
the prednisone group, 64% reached 100% as compared to 57% (p>O.OS). It was 
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Figure 6. 1 00% speech discrimination scores, as a function of time. The percentage of patients with maximal speech 
discrimination, for both patient groups. 
DISCUSSION 
This prospective, randomized, double-blind clinical trial, comparing high dose 
dexamethasone and prednisone in the treatment of iSSHL, was the result of a unique 
co-operation among all academic hospitals in the Netherlands and a great many 
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regional hospitals. Faced with a disease entity like ISSHL, where no clear aetiology or 
consensus of treatment exists, all participating centres set aside their differences and 
made this study possible. 
Our results showed that in the treatment of ISSHL, dexamethasone showed no clear 
advantage over "standard" dose prednisone. 
Our secondary endpoints, such as tinnitus, vertigo and a pressure sensation, all 
improved. Tinnitus, which affected 85% to 90% of patients in our study group, has a 
poor prognosis and remains a lasting disturbing consequence ofiSSHL. Pulse therapy 
had no extra beneficial effect on the prognosis for tinnitus. Pressure sensation and 
vertigo reacted more favourably to treatment. 
Corticosteroids are pleiotropic hormones that at pharmacological doses prevent 
or suppress inflammation and other immunologically mediated processes 15• 
Corticosteroids may play a role in the regulation of ionic and fluid dynamics in the 
inner ear, since the sodium, potassium and Na, K-ATPase sites of the lateral wall of 
the inner ear are modulated in accordance with the presence or absence of circulating 
glucocorticoids. Corticosteroid administration correlates with increased levels of Na, 
K-ATPase in the inner ear 9• 
Inhibition of leukocyte traffic and cellular immune responses require lower doses of 
glucocorticoids, higher doses of these agents are needed to suppress the functions 
of leukocytes and the humoral immune response 15 •  Higher doses of systemic 
glucocorticoids can be administered for less than a week with relative safety, although 
the same dose of drug administered for a more extended period will result in 
predictable, clinically significant morbidity. The aim of pulse therapy is to suppress 
both the humoral and cellular immune response in relative safety. 
In ISSHL, the delicacy of the structures involved makes elucidation of and interference 
with its pathophysiology difficult. In our opinion, no truly successful treatment 
regimen can be offered to patients with ISSHL, despite the mildly beneficent effect 
of corticosteroids. Although we have not been able to ascertain an advantage of 
pulse therapy over 'standard' prednisone therapy in this study, some methodological 
limitations are apparent that might explain our results in part. 
We hypothesized that we would need 102 patients to detect a 10  dB hearing recovery 
difference between our study groups. Even with a multicentre approach we included 
only 91  patients over four years, before being forced to stop because oflogistical reasons. 
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This group may still have been too small to achieve statistical significance, especially 
when you consider the large range (SO) of both hearing loss at admission and after 12 
months. Second, for any therapeutic technique in ISSHL to show efficacy, its success 
rate would have to significantly exceed the high spontaneous recovery rate reported of 
between 40% and 65% 1 • Third, ISSHL is probably multifactorial in origin and the 
failure as a group to benefit from Pulse Therapy does not exclude the possibility that 
a subgroup is highly responsive to this treatment. 
CoNCLUSION 
This study showed that pulse therapy is equally effective and safe as standard-dose 
prednisone. Pulse Therapy suppresses both humoral and cellular immune responses 
and therefore should have a wider anti-inflammatory effect. 
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SUMMARY AND CONCLUSIONS 
Chapter 7 
SUMMARY 
Idiopathic sudden sensorineural hearing loss (ISSHL) is characterized by sensorineural 
hearing loss that develops within 24 hours in otherwise healthy, normally hearing 
individuals. The hearing loss is of unknown origin and can be mild to profound, 
temporary or permanent. A known cause can be identified in only 10-1 5% of cases, 
even after an extensive evaluation. In the majority of cases the hearing loss is unilateral, 
but on occasion both ears are involved. The hearing loss is frequently associated with 
vestibular disturbances, tinnitus and a pressure sensation in the ear. Some spontaneous 
hearing recovery is reported to occur in 45-65% of cases, although only in a small 
number of cases will hearing recover to functional levels. The estimated incidence 
of ISSHL is between 5-20 persons per 1 00,000 annually. The true incidence is not 
known because there are groups of patients who may not seek treatment following 
spontaneous recovery. There is no gender difference or geographical predominance in 
sudden hearing loss, nor are there seasonal influences. 
Most patients present themselves with hearing loss that occurs instantly, often 
accompanied by the perception of a loud sound, while some develop the hearing loss 
rapidly progressive. The subjective loss of hearing may first be noticed on awakening or 
when using the phone. There may be hearing loss in all frequencies, a predominantly 
high or low tone loss, or a complete loss of hearing. Tinnitus may be the symptom 
that brings the patient to the physician's office. This symptom occurs in about 80% 
of patients and can precede the hearing loss. It often persists and can be extremely 
uncomfortable. A mild form of vertigo affects 40% of patients, while 1 0% can have a 
more severe form. Other symptoms include a sensation of aural pressure or headache. 
Vertigo and a pressure sensation have a good prognosis, in only 10% of the population 
do these symptoms persist. An upper respiratory infection occurs in about 30% of 
cases preceding the hearing loss. 
Prognostic factors in ISSHL mentioned in the literature include vertigo, the shape of 
the audiogram, and the severity of the initial hearing loss. In general, patients with 
mild to moderate hearing loss without vertigo who are seen (and treated) quickly after 
the initial onset of the hearing loss will have a better chance of recovery. 
Of the patients presenting sudden hearing loss, a cause will be found in 10- 1 5% of 
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cases. The remaining 85-90% has true idiopathic loss. There are four main theories 
regarding the aetiology: viral infection, disturbances in the microcirculation, inner ear 
membrane leaks and immunopathological processes. The difficulties in elucidating 
the aetiology, therefore also the therapy, ofiSSHL might be attributed to three factors. 
The condition's low incidence, especially when inclusion and exclusion criteria are 
strictly applied, makes the inclusion of sufficient patients to evaluate new therapies 
difficult. The biggest problem, however, is the closed delicate compartment formed 
by the inner ear, which does not permit diagnostic samples to be taken. Furthermore, 
evaluation of treatment is hampered by the lack of a definition of ISSHL, which 
makes comparison of trials difficult, and the tendency for spontaneous recovery, which 
makes the contribution of therapy to hearing recovery difficult to assess. 
In this thesis the definition of ISSHL is: 1 )  a perceptive hearing loss of unknown 
aetiology; 2) hearing loss of at least 30 dB hearing level (HL) for 3 subsequent 1 -
octave steps in  the standard pure tone audiogram (PTA); 3) Hearing loss occurred 
within twenty-four hours; 4) blank otologic history of the affected ear. 
Chapter 2 reviews the literature on the aetiology and therapy of ISSHL. The main 
theories concerning the aetiology of ISSHL are ( 1 )  vascular disturbances, (2) sub 
clinical viral labyrinthitis, (3) inner ear membrane leaks and (4) immunopathological 
processes. Each theory is evaluated and relevant treatment modalities compared. 
After 60 years of research, aetiology and treatment are still unproven. It even remains 
uncertain whether ISSHL is a symptom or a disease. All trials suffer from poor design 
and (too) small patient populations. Even when well designed, no true placebo has 
been tested. A high-dose steroid is the only therapy to yield some improvement in 
hearing recovery, although even this is not universally accepted. Vasoactive therapy 
shows only minor advantages in a small subset of parameters. Our theory that ISSHL 
is most probably the result of a (sub clinical) viral infection of the inner ear which 
leads to an immune response, as a result of which the hearing loss occurs, still stands. 
Chapter 3. A viral cause of ISSHL was hypothesized because clinical observations 
reported an upper respiratory infection preceding ISSHL in about 30% of cases. 
This led to the supposition of a viral cochlear labyrinthitis to cause ISSHL. Reports 
of seroconversion of herpes antibody titers and the presence of latent neurotropic 
herpes viruses in the spiral ganglia of asymptomatic individuals have drawn attention 
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to the possible role of this virus family in causing ISSHL. A possible mechanism 
could be a latent virus infection and its reactivation. Herpes simplex virus type 1 
and 2, varicella zoster virus and cytomegalovirus(HSV-1 ,  HSV-2, VZV, CMV) all 
have a strong neurotropism and have been detected in human post mortem spiral, 
geniculate, trigeminal and vestibular ganglia. 
In this study, specimens from fresh nervous tissue of the inner ear of 2 1  unselected 
patients were taken during operations in which access had to be gained to the 
cerebellopontine angle. Samples of the inner ear were analyzed by polymerase chain 
reaction analysis (PCR) for HSV- 1 ,  HSV-2, VZV and CMV. Under the hypothesis 
that ISSHL is the result of a reactivation of a herpes family virus, latent virus should 
be present and detectable in a proportion of the "normal" population. 
In our patient group we detected only two positive PCR-reactions for CMV and three 
dubious positives for VZV and CMV. None of the samples were positive for HSV. 
The failure to detect a herpes simplex virus in our series and the very low incidence of 
CMV and VZV was unexpected. Worldwide, more than 90% of people are seropositive 
for HSV-1 by their fourth decade of life. The high prevalence of herpes viruses in the 
general population is undisputed and therefore our failure to detect these viruses is 
probably due to methodological issues rather than absent virus. 
Chapter 4 presents a prospective, randomized, double-blind clinical trial. This study 
was based on the theory that a viral infection of the inner ear, probably a herpes 
simplex virus, is the cause of ISSHL. 
The therapeutic value of the anti-herpetic drug acyclovir was evaluated by studying 
the hearing recovery in 91 patients with ISSHL who also received prednisone. The 
audiometric parameters included pure tone and speech audiometry. Subjective 
parameters studied included hearing recovery, a pressure sensation in the affected 
ear, vertigo and tinnitus. A one-year follow-up was obtained. Hearing recovery for 
the whole group averaged about 35 dB and was independent of initial hearing loss 
or vestibular involvement. Tinnitus, occurring in a majority of patients, had a poor 
prognosis. There was no difference in hearing recovery, speech discrimination or 
subjective parameters between the acyclovir and the prednisone group. We conclude 
on the basis of this study that no beneficial effect from combining acyclovir with 
prednisone can be established in patients with ISSHL. 
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In Chapter 5 the bioavailability of a new 50 mg dexamethasone tablet was assessed 
for use in four patients with pemphigus vulgaris. This was a co-operation with the 
departments of Dermatology and Otorhinolaryngology. 
A pulse of 300 mg dexamethasone in the form of six 50 mg tablets was administered 
orally. Serum concentrations of dexamethasone were measured by high-performance 
liquid chromatographic procedure with diode-array UV detection. The mean 
bioavailability of oral high-dose dexamethasone was about 60% of 200 mg 
dexamethasone administered intravenously. We conclude that dexamethasone in a 50 
mg tablet formula is suitable for oral high-dose glucocorticoid pulse therapy. 
Chapter 6. A new study was designed where our hypothesis was that a sub clinical 
virus infection of the inner ear triggers an immune response which in turn causes 
the hearing loss. A strong suppression of the immune reaction by pulse therapy with 
high dose dexamethasone, should lead to better hearing recovery as compared to 
"standard" dose prednisone. In a randomized, prospective, double-blind, multicentre 
clinical trial, we recruited 8 1  patients with ISSHL. Patients were randomly allocated 
to pulse therapy (300 mg dexamethasone for 3 consecutive days followed by four days 
of placebo) or control treatment (prednisone 70 mg per day tapered in steps of 10  mg 
per day to 0 mg) . The primary outcome was hearing recovery as measured by pure tone 
audiometry and speech audiometry after 12 months. The secondary outcomes were 
subjective parameters like hearing recovery, tinnitus, vertigo and a pressure sensation. 
Overall improvement of pure tone thresholds and speech discrimination scores was 
slightly but not significantly better in patients given dexamethasone than those 
given standard prednisone. Hearing improved from 71 dB HL to 36 dB HL in the 
dexamethasone group and from 75 dB HL to 42 dB HL in the prednisone group. 
Speech discrimination scores of 100% were attained by 64% of dexamethasone­
treated patients and 57% in the prednisone group. 





The results of the treatment of ISSHL remain unsatisfactory. In this thesis, two 
systematic studies have evaluated different aspects of the etiology, and therefore 
treatment, of ISSHL. Both studies compared the experimental treatment with 
"standard" dose prednisone. Based on the literature when the studies were performed, 
prednisone had a small but positive effect on hearing recovery. We felt it was unethical 
to withhold our patients this treatment, therefore no placebo was used. The first study 
was based on the theory that a viral labyrinthitis, probably a herpes virus, is the cause of 
the hearing loss. The addition of acyclovir however, did not improve hearing recovery. 
The second study was based on the theory that a (viral) infection or reactivation of 
a viral infection in the inner ear causes an immune reaction which in turn causes the 
hearing loss. Pulse therapy is used to suppress both the humoral and cellular immune 
reaction. Suppression of this immune reaction should lead to better hearing recovery. 
This study did not show a difference between the study groups. 
Where does this leave us? Is treatment of ISSHL necessary? Which treatment gives 
the best results? These are fundamental questions to which there are no easy answers. 
Additional obstacles in the study of ISSHL are an absence of a clear definition of the 
disease and recovery, the low incidence and the high rate of spontaneous recovery. 
These factors greatly contribute to the general low quality of available studies. 
As far as the etiology is concerned there are still two main theories left; one is the 
theory concerning vascular disturbances in the inner ear, the other is the labyrinthitis 
I immunopathological group. This last theory is often presented as two different 
theories but I think we must conclude that they represent a spectrum of similar 
pathophysiologies. Both main theories, however, might well be interrelated and 
influence each other. 
In accordance with the Cochrane collaboration, a few advises can be given. 
First it is imperative that a clear and internationally accepted definition of ISSHL is 
formulated. Second it is important that an accepted definition of recovery is defined. 
These two factors will greatly improve the comparison of different studies. 
So far, the treatment of ISSHL has been unsatisfactory. Small successes have been 
reported, but on the whole, results have been disappointing. The need for systematic 
reviews of existing studies and methodically well executed new studies, always 
comparing the experimental treatment with a placebo, seem to be the route towards 
elucidating a better treatment option. Due to the low incidence, multicenter studies 
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are necessary. Furthermore, all patients must undergo a diagnostic protocol to rule out 
any known causes of hearing loss. 
In the University Medical Center Groningen all patients with an unexplained hearing 
loss follow a diagnostic protocol: this includes a complete history and physical 
examination, audiological and vestibular tests, magnetic resonance imaging of the 
temporal bone and cerebellopontine angle, and laboratory work-up. Laboratory 
investigations are aimed at excluding the presence of an infectious, inflammatory, 
autoimmune process or coagulopathy. This includes viral and bacterial serology. After 
the provisional diagnosis ISSHL is made, all patients are treated with the dexamethasone 
pulse therapy. This is based on our belief that the immune reaction plays a large role in 
the hearing loss and recovery. Furthermore, pulse therapy has a theoretical wider anti­
inflammatory effect compared to standard dose prednisone and a three days of pulse 
therapy is equally effective as a seven day course of tapered prednisone. 
fUTURE PERSPECTIVES 
The next step should be a methodologically sound trial comparing prednisone and 
placebo, although some might think this is unethical. However, first this should, once 
and for all, close the discussion about the effectiveness of prednisone. Secondly, a 
meta-analysis is underway by the Cochrane Collaboration evaluating the effectiveness 
of vasoactive treatment. Further studies of vasoactive treatment should also compare 
with a placebo. If, and only when positive results have been found, should vasoactive 
treatments be compared with prednisone. A combination of vasoactive treatments and 
prednisone might have a synergistic effect, but this can only be concluded after each 
separate treatment has been tested against a placebo. 
Overcoming the inherent difficulties in the study of ISSHL poses major problems, 
but they should be solvable. This is what we owe to our patients, who come to us 







ldiopathisch plots perceptief gehoorverlies (Engels: Idiopathic Sudden Sensorineural 
Hearing Loss, ISSHL) wordt gekenmerkt door een perceptief gehoorverlies dat binnen 
24 uur ontstaat in verder gezonde, normaal horende person en. Na uitgebreid onderzoek 
kan in slechts 1 0  - 1 5o/o van de gevallen een onderliggende oorzaak gevonden warden. 
Het gehoorverlies kan mild of ernstig zijn, tijdelijk of permanent. Bij een overgrote 
meerderheid van de patienten treedt het gehoorverlies slechts aan een oor op, zelden aan 
beide oren. Het gehoorverlies kan gepaard gaan met evenwichtsstoornissen, oorsuizen 
of een drukgevoel in of rond het oor. Bij 45-65% van de patienten is er sprake van 
spontaan herstel, hoewel dit bij de meeste patienten niet volledig is. ISSHL komt bij 
5-20 personen per 100,000 mensen per jaar voor. Het precieze aantal personen met 
ISSHL is onbekend omdat sommige personen geen dokter bezoeken als het gehoor in 
de tussentijd hersteld is. Er zijn geen seizoens-, geslachts-, of geograflsche invloeden 
op het krijgen van ISSHL bekend. Wel is in 30o/o van de gevallen sprake geweest van 
een bovenste luchtweg infectie in de maand voorafgaand aan het gehoorverlies. 
Patienten kunnen zich presenteren met een plots ontstaan volledig gehoorverlies, of 
met een snel verergerend gehoorverlies. Het gehoorverlies wordt vaak bij het opstaan 
of telefoneren bemerkt. Het gehoorverlies kan zich op alle toonhoogtes voordoen, 
soms alleen voor de hoge of de lage tonen, soms totaal. Naast het gehoorverlies is 
oorsuizen een veelgenoemde hinderlijke klacht. Oorsuizen treedt op in ongeveer 80o/o 
van de gevallen en kan aan het gehoorverlies voorafgaan. Bij 60o/o van de patienten 
met oorsuizen verdwijnen deze klachten niet. 
Een milde vorm van duizeligheid treedt bij ongeveer 40o/o van de patienten op, bij 
1 Oo/o zijn de klachten zo hevig dat het onmogelijk is om rechtuit te lopen. Een derde 
van de patienten heeft last van een drukkend gevoel in of rondom het oor. Echter, 
evenwichtstoornissen en drukklachten hebben een gunstige prognose. Slechts 1 Oo/o 
van de patienten blijft hier last van houden. 
Voorspellende factoren voor het herstel zijn de aan- of afWezigheid van 
evenwichrsstoornissen, het soort gehoorverlies en de ernst van het gehoorverlies. In 
het algemeen hebben jonge patienten met een mild tot matig gehoorverlies zonder 
duizeligheid, die snel warden behandeld na het begin van het gehoorverlies, de beste 
kans op gehoorherstel. 
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Werking van het oor 
Voor het begrip van de verschillende theorieen over het ontstaan van ISSHL is het 
belangrijk om iets over de werking van het gehoororgaan uit te leggen. 
In Figuur 1 is een tekening van het gehoororgaan weer gegeven. Geluid is een trilling 
die via de oorschelp binnenkomt, waarna het trommelvlies deze trilling via drie kleine 
gehoorbeentjes doorgeeft aan het slakkenhuis (het binnenoor) . 
Hier wordt de geluidstrilling door speciale zintuigcellen omgezet in een elektrisch 
signaal dat dan via de gehoorzenuw naar de hersenen gaat. Gehoorsverlies dat optreedt 
vanaf de oorschelp tot aan de cochlea wordt een geleidingsslechthorendheid genoemd. 
Gehoorverlies dat optreedt in het traject vanaf de cochlea tot aan de hersenen 
wordt perceptieve slechthorendheid genoemd. ISSHL is een vorm van perceptieve 
slechthorendheid. 
Figuur 1. 
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Chapter S 
Drie eigenschappen van ISSHL bemoeilijken het onderzoek naar de oorzaak en 
behandeling ervan. Ten eerste komt ISSHL weinig voor, waardoor het heel moeilijk 
is om genoeg patienten mee te laten doen om nieuwe behandelmodaliteiten te 
onderzoeken. Om wetenschappelijk verantwoorde conclusies te kunnen trekken is het 
noodzakelijk dat de patientengroepen groat genoeg zijn. Ten tweede is het binnenoor 
zeer kwetsbaar en moeilijk toegankelijk voor onderzoek. Als er een monster uit het 
binnenoor wordt genomen, wordt het oar doof. Dit is ontoelaatbaar bij een ziekte 
waar in 45 tot 65% van de patienten het gehoor in meer of mindere mate herstelt. 
Verder wordt het onderzoek gehinderd door het onrbreken van een duidelijke deflnitie 
van ISSHL en de a! eerder genoemde neiging tot spontaan herstel, waardoor de 
effectiviteit van de behandeling moeilijk aan te tonen is. 
De deflnitie van ISSHL, zoals gebruikt in dit proefschrift, is 1) een perceptief 
gehoorverlies van onbekende herkomst; 2) gehoorverlies van ten minste 30 dB voor 
drie opeenvolgende octaven in het standaard toonaudiogram; 3) het gehoorverlies 
ontstaat binnen 24 uur; 4) blanco otologische voorgeschiedenis aan het aangedane 
oar. 
Hoofdstuk 2. In dit hoofdstuk warden de vier belangrijkste theorieen over de 
ontstaanswijze van ISSHL besproken met hun behandelingen. 
De vier belangrijkste theorieen die ISSHL proberen te verklaren zijn: 
- een onopgemerkte virale ontsteking van het binnenoor, 
- doorbloedingsstoornissen van het binnenoor, 
- een sponrane membraanruptuur van het binnenoor en 
- een immuunstoornis van het binnenoor. 
Elke theorie wordt geevalueerd en de verschillende behandelopties warden naast elkaar 
gelegd. 
Na zestig jaar onderzoek zijn oorzaak en behandeling nog steeds niet opgehelderd. Het 
is zelfs onduidelijk ofiSSHL een symptoom of een ziektebeeld is. Alle publicaties lijden 
aan tekortkomingen in de onderzoeksmethoden en te kleine aantallen patienten. Zelfs 
in goed uitgevoerde studies wordt niet vergeleken met een placebobehandeling. Enkele 
studies wijzen op een beperkt gunstig effect van behandeling met corticosterolden 
op het herstel na ISSHL. Medicijnen tegen doorbloedingsstoornissen laten alleen in 
beperkte subgroepen kleine voordelen zien. Onze theorie dat ISSHL een onopgemerkte 
virale ontsteking van het binnenoor is, met als gevolg daarvan een immuunreactie die 
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de schade aan het binnenoor veroorzaakt, en dus ook het gehoorverlies, staat nog 
steeds. 
Hoofdstuk 3. In dit hoofdstuk wordt een studie besproken waarin onderdelen van 
het binnenoor worden onderzocht op bepaalde virussen met behulp van PCR-analyse 
(aantonen van DNA van de verschillende virusdeeltjes) . Delen van het binnenoor 
werden onderzocht op de aanwezigheid van het herpes simplexvirus (HSV) type 1 
en 2, cytomegalovirus (CMV) en varicella zostervirus (VZV). Een virale oorzaak 
van ISSHL werd geopperd als hypothese omdat uit klinische observaties bleek dat er 
sprake was van een bovenste luchtweginfectie in ongeveer 30% van de patienten met 
ISSHL. Daarnaast werden in het bloed aanwijzingen gevonden voor seroconversie 
voor herpesvirussen. 
Herpes simplex type 1 en 2, varicella zostervirus en cytomegalovirus ( HSV- 1 ,  HSV-
2, VZV en CMV) zijn allemaal aangetoond bij postmortem onderzoek in menselijk 
ganglion spirale, geniculate, trigeminale en vestibulaire. Een mogelijk mechanisme 
hiervoor zou een latente virus infectie met reactivatie kunnen zijn. Het is bekend dat 
een groot gedeelte van de "normale" populatie besmet is met een van bovengenoemde 
virussen en deze virussen zouden dan ook verantwoordelijk kunnen zijn voor de 
onopgemerkte virale ontsteking van het binnenoor, met ISSHL als gevolg. 
In deze studie werd bij 2 1  patienten, die aan de brughoekregio werden geopereerd 
en waarbij het binnenoor moest worden opgeofferd, vers zenuwweefsel verzameld en 
onderzocht op bovengenoemde virussen door middel van PCR-analyse. 
De hypo these was dat als ISSHL het resultaat is van de reactivatie van een latent herpes 
virus in het binnenoor, deze ook moest kunnen worden aangetoond in ongeselecteerde 
individuen. 
In onze patientgroep kon in slechts 2 binnenoormonsters CMV worden aangetoond, 
in 3 binnenoormonster kon zeer beperkt CMV en VZV worden aangetoond. In geen 
van binnenoormonscers kon HSV worden aangetoond. De afwezigheid van HSV en de 
zeer beperkte aanwezigheid van CMV en VZV kwam als een verrassing. Wereldwijd is 
meer dan 90% van de populatie besmet met HSV vanafhet veertigste levensjaar. Deze 
hoge aanwezigheid van HSV is onbetwist en wij denken dan ook dat in onze studie 
er eerder een probleem is geweest met het verzamelen van de binnenoormonsters dan 
dat deze populatie niet besmet zou zijn geweest met deze virussen. 
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Hoofdstuk 4 presenteert de resultaten van een prospectief, gerandomiseerd dubbelblind 
klinisch onderzoek. Dit onderzoek ging uit van de theorie dat ISSHL wordt veroorzaakt 
door een virale ontsteking van het binnenoor, waarschijnlijk door een herpes virus. In 
deze studie werd de toevoeging van het antiherpetische medicijn aciclovir vergeleken 
met een placebo op het gehoorherstel bij 9 1  patienten met ISSHL beschreven. Beide 
groepen kregen daarnaast ook de standaardbehandeling met prednison. Het primaire 
eindpuntwas het gehoorherstel gemeten met toon-en spraakaudiometrie. De subjectieve 
parameters die onderzocht werden zijn het gehoorherstel, drukgevoelens in het oor, 
evenwichtsstoornissen en oorsuizen. De follow-up bedroeg 1 jaar. Het gemiddelde 
gehoorherstel voor de hele groep was ongeveer 35 dB en was onafhankelijk van de 
mate van het gehoorverlies of de aanwezigheid van evenwichtssroornissen bij inclusie 
van het onderzoek. Oorsuizen, dat voorkwam bij een meerderheid van de patienten 
gaf een slechte prognose. Er was geen verschil in gehoorherstel, spraakaudiometrie, of 
subjectieve parameters als we beide behandelingsgroepen vergeleken met elkaar. De 
conclusie was dat toevoeging van aciclovir aan prednison geen toegevoegde waarde 
heeft bij de behandeling van ISSHL. 
In hoofdstuk 5 werd de biologische beschikbaarheid onderzocht van een nieuw 
dexametasontablet van 50 mg in de behandeling van 4 patienten met Pemphigus 
Vulgaris. Dit was een samenwerkingsverband tussen de afdelingen Dermatologie en 
Keel-, Neus-, en Oorheelkunde. 300 mg dexametason werd als pulstherapie gegeven 
in de vorm van 6 tabletten van 50 mg. 
De biologische beschikbaarheid bedroeg 60%. Hieruit concludeerden we dat de 
nieuwe dexametasontabletten van 50 mg geschikt zijn voor toepassing in een orale, 
hooggedoseerde, corticosteroid pulstherapie. 
Hoofdstuk 6. In een nieuw prospectief, gerandomiseerd, dubbelblind, multicenter 
klinisch onderzoek werden 8 1  patienten met ISSHL gerekruteerd. Onze theorie naar 
de etiologie was aangepast na de teleurstellende resultaten van het aciclovironderzoek. 
Een (sub)klinische virale ontsteking zou nog steeds ISSHL kunnen veroorzaken, maar 
vooral omdat de virusontsteking een immuunreactie oproept die verantwoordelijk is 
voor het gehoorverlies. Een sterkere onderdrukking van het immuunsysteem zou dus 
een betere kans op herstel moeten geven. 
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Patienten werden gerandomiseerd waarbij de ene groep pulstherapie kreeg (300 mg 
dexametason per os gedurende drie opeenvolgende dagen gevolgd door 4 dagen 
placebo) en de andere groep de standaardtherapie (prednison 70 mg per os, in een 
afbouwschema van 10 mg per dag tot 0 mg) . Ook hier was de primaire uitkomst 
het gehoorherstel na 1 jaar, zoals gemeten met toondrempel- en spraakaudiometrie. 
Secundaire uitkomsten waren subjectieve parameters als gehoorherstel, drukgevoelens, 
duizeligheid en oorsuizen. Het gehoorherstel in de pulstherapie groep was iets beter, 
maar niet significant, dan in de controlegroep. Het gehoor herstelde van 7 1  dB HL 
naar 36 dB HL in de dexametasongroep en van 75 dB HL naar 42 dB HL in de 
prednisongroep. 100% spraakdiscriminatiescore werd gehaald in 64% van de patienten 
in dexametasongroep en in 57% van de patienten in de prednisongroep. 
Pulstherapie is daarmee net zo effectief en veilig als standaarddosering prednison. 
Pulstherapie remt zowel de humorale als de cellulaire immuunreactie en heeft daardoor 
theoretisch een breder werkingsspectrum dan de "standaard" dosering prednison. 
CoNCLUSIES 
De resultaten van de behandeling van ISSHL zoals beschreven in dit proefschrift blijven 
onbevredigend. In dit proefschrift zijn rwee prospectieve, dubbelblinde, multicenter 
klinische studies beschreven die systematisch een onderdeel van de behandeling 
hebben onderzocht. Beide studies vergeleken met een "standaard" behandeling met 
prednison, omdat ten tijde van de start van het onderzoek er een klein maar significant 
beter gehoorherstel was gevonden bij patienten die waren behandeld met prednison. 
Wij vonden het daarom onethisch om geen prednison te geven. De eerste studie was 
gebaseerd op de theorievan een virale labyrinthitis, meestwaarschijnlijk een herpesvirus, 
als oorzaak van de ISSHL. De toevoeging van acyclovir gaf geen beter gehoorherstel. 
De rweede studie was gebaseerd op de theorie dat weliswaar een virale labyrinthitis 
het begin was, maar dat vooral de immuunreactie hierop de grootste schade aan het 
binnenoor gaf. Pulstherapie geeft een bredere onderdrukking van het immuunsysteem 
dan prednison en zou daardoor een grater gehoorherstel moeten geven. Pulstherapie 
gaf een vergelijkbaar gehoorherstel als de standaarddosering prednison. 
En nu? Moeten we ISSHL wel behandelen? Zo ja, waarmee? 
Dit zijn de fundamentele vragen die na 60 jaar onderzoek nog steeds niet zijn opgelost. 
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Problemen bij het onderzoek naar de etiologie en behandeling van ISSHL zijn het 
gebrek aan een internationaal erkende deflnitie van het ziektebeeld en van herstel, 
de lage incidentie en het hoge spontane herstel. Deze intrinsieke factoren zijn een 
belangrijke reden voor de algemeen lage kwaliteit van beschikbare studies. 
Wat betreft de etiologie zijn 2 theorieen overgebleven: een doorbloedingsstoornis 
van de cochlea en een labyrinthitis I immuunstoornis van de cochlea. Het is niet 
ondenkbaar dat deze hoofdtheorieen elkaar be"invloeden. De laatste theorie wordt 
vaak gepresenteerd als twee gescheiden theorieen, echter het is waarschijnlijk dat er 
een grote onderlinge sarnenhang bestaat. 
Evidence Based Medicine, zoals uitgedragen door de Cochrane Collaboration, 
biedt wel aanknopingspunten voor verder onderzoek. Ten eerste moet een algemeen 
geaccepteerde deflnitie van ISSHL worden gevonden. Ten tweede moet er een 
deflnitie van herstel komen en een manier waarop dit moet worden berekend. Alleen 
al het beschikbaar komen van deze twee deflnities zal bijdragen aan de kwaliteit en 
vergelijkbaarheid van toekomstige studies. 
De behandeling van ISSHL blijft onbevredigend. Kleine successen worden gemeld, 
maar in het algemeen zijn de resultaten niet beterdan het spontane herstel. Systematische 
reviews en methodologisch juist uitgevoerde studies die altijd vergelijken met een 
placebo lijken wel de manier om een antwoord te vinden. Multicenter onderzoek lijkt 
onontkoombaar gezien de lage patientaantallen. 
In het Universitair Medisch Centrum Groningen worden alle patienten met een 
plotseling gehoorverlies volgens een richdijn behandeld. Zij doorlopen allemaal een 
diagnostisch protocol dat gericht is op het uitsluiten van een bekende, en mogelijk 
behandelbare, oorzaak van het gehoorverlies. Dit houdt in: anarnnese en onderzoek, 
audiometrie en vestibulaire testen, MRI van de brughoek en laboratoriumonderzoek. 
Het laboratoriumonderzoek is gericht op het uitsluiten of aantonen van een infectieus, 
inflarnmatoir, of auto-immuunproces, of een stollingsstoornis. Hieronder valt ook 
uitgebreide virus- en bacteriele serologie. Nadat de werkdiagnose ISSHL is gesteld 
worden alle patienten behandeld met dexarnethason pulstherapie. 
Dit is gebaseerd op onze theorie dat de immuunreactie een grate rol speelt in het 
gehoorverlies en gehoorherstel en pulstherapie een theoretisch breder werkingsproflel 
heeft dan de "standaard" dosering prednison. Verder blijkt de pulstherapie in drie 




De volgende stap in het onderzoek naar ISSHL zou een methodologisch goed 
uitgevoerde trial moeten zijn waarbij prednison (of pulstherapie) wordt vergeleken 
met een placebo. Dit lijkt misschien onethisch, maar hiermee moet duidelijk 
worden of een behandeling met prednison zinvol is. De Cochrane Collaboration is 
nu bezig met een systematische review naar de effectiviteit van behandelingen tegen 
doorbloedingsstoornissen van de cochlea. Behandelingen van doorbloedingssroornissen 
van de cochlea moeten (hierna) ook worden vergeleken met een placebobehandeling. 
Alleen wanneer positieve resultaten worden gevonden kunnen beide behandelingen 
met elkaar vergeleken worden. Een combinatie van vasoactieve therapieen en prednison 
zouden zelfs synergistisch kunnen werken, echter dit is alleen met zekerheid te zeggen 
nadat beide behandelingen afz.onderlijk zijn vergeleken met een placebo. 
Het onderzoek naar de etiologie en behandeling van ISSHL is nog lang niet afgerond. 
Zoals gebruikelijk levert dit proefschrift dan ook meer vragen dan antwoorden op. 
Het systematisch toetsen van ideeen en behandelingen is een langzame weg, waar ook 
negatieve resultaten bijdragen aan een toenemende kennis van het ziektebeeld Sudden 
Deafness. Het overwinnen van alle hindernissen in het onderzoek naar ISSHL kost 
veel tijd, geld en energie. Dit is wel een moeite die we moeten nemen voor al onze 





De totstandkoming van dit proefschrift was een langdurig proces. Een aantal mensen 
wil ik in het bijzonder bedanken, zonder wiens hulp dit mogelijk niet volbracht had 
kunnen worden. 
Pro£ dr. F.W.J. Albers. Zonder uw hulp, begeleiding en coaching was dit proefschrift 
waarschijnlijk nooit afgerond. Uw steun gedurende de opleiding en uw vertrouwen in 
mij dat ik beide zou volbrengen zijn van onschatbare waarde geweest. Ook gedurende 
de laatste fase van dit proefschrift waarin u zich terug trok, deels ten gevolge van de 
verandering in uw werkomgeving en deels ten gevolge van uw ziekte, dat u helaas fataal 
is geworden, en het mij alleen liet afmaken zijn bepalend geweest voor de afronding 
hiervan. Ik had graag nog veel van u willen leren. Voor dit alles zal ik u altijd onthouden 
en ben ik u zeer dankbaar. 
Dank aan alle deelnemende patienten die hebben meegewerkt aan dit onderzoek. Om 
op het moment dat een deel van de zekerheden van dit leven wegvalt, mee te werken aan 
wetenschappelijk onderzoek getuigt van grote moed. 
Pro£ dr B.F.A.M van der Laan, Beste Bernard. Dank voor de begeleiding van de laatste, 
doch cruciale fase van dit proefschrift. De laatste loodjes wegen het zwaarst zeggen ze, 
en nu is het klaar. Als beedigd professor ben ik je eerste promovendus, ik hoop dat er 
nog vele zullen volgen. 
Dr. R.J. Stokroos. Als jouw opvolger in het onderzoek naar plotselinge doofheid ben ik 
jou zeer erkentelijk voor al het werk wat je hebt gedaan. Jouw proefschrift over ISSHL 
is altijd een gids gebleven. 
Pro£ dr. ir. H.P. Wit. Zonder uw kennis van statistiek en de mogelijkheden om dit 
visueel te presenteren was dit proefschrift nooit zo helder geworden. 
Dr. ir. E de Kleine, Beste Emile. Jouw nuchtere kijk op statistiek heeft mij behoedt 
voor al te enthousiaste voorspellingen die ik niet kon waarmaken. Dankzij jou zijn de 
conclusies ook wetenschappelijk verantwoord en in goed Nederlands verwoord. 
Beoordelingscommissie, hartelijk dank voor uw tijd en deskundige beoordeling. 
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Alle assistenten van KNO Nederland. Jullie steun bij het includeren van patienten en de 
vele uren die jullie hiermee bezig waren zijn niet vergeten. Mijn dank hiervoor. 
Alle afdelingshoofden van KNO-afdelingen. De medewerking aan een landelijk 
onderzoek naar een ziektebeeld waarvan de etiologie en met name de therapie nog open 
is voor vele verschillende interpretaties, getuigt van visie. 
Prof. Dr. 0. van Nieuwenhuizen, Beste Onno, Jij bent altijd een van mijn voorbeelden 
geweest, zowel medisch als sociaal. Goed voorbeeld doer goed volgen. 
Dr. R. Free, Beste Rolien. Jouw steun en motivatie en door het goede voorbeeld te geven 
hebben zeker bijgedragen aan het volbrengen van dit proefschrift. 
Beste Arie en Arine, jullie interesse en trots in mij dat ik als eerste Westerlaken ging 
promoveren, zijn een belangrijke motivatie geweest am dit af te ronden. Oak het 
vooruitzicht op een spetterend feest bracht licht aan het einde van de tunnel. Dank 
voor alle mogelijkheden die jullie mij hebben geboden, proeven van de wereld en veel 
reizen. 
Yo sista, there can only be one. 
Lieve Danielle. Jij hebt mij gegeven war ik zocht en nodig heb. Samen met jouw kan ik 
de hele wereld aan. Door jouw keuze am jouw lot te verbinden aan het mijne heb je mij 
alle vrijheid gegeven am te kiezen. Het rotsvaste verrrouwen dat ik de juiste keuze zal 
maken betekent meer voor mij dan je beseft. 
Floorrje, je vrolijkheid doer wonderen. De wereld ligt aan je voeten. 
Hasse, nieuwste Westerlaken telg. Alle wijsheid en liefde die ik kan geven, krijg je. 
Boris Olivier Westerlaken 
Mei 2008 
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